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Abstract 
During infection or inflammation pituitary hormone production is altered in a specific 
manner to adapt the endocrine system to the activated immune system. One major class 
of innate receptors, the NOD-like receptors, are known as PRRs (pattern recognition 
receptors) and involved in the early immune response upon bacterial infection through 
the activation of downstream signaling pathways, including NF-κB (nuclear factor kappa 
B) and other important signaling pathways. Here, we investigated the expression and 
activation of NOD (nucleotide oligomerization domain) immune receptors in AtT20 
pituitary tumor cells and in pituitary adenomas. Moreover, it could be hypothesized that 
the PI3K/AKT pathway plays a role in NOD signaling-induced pituitary tumor survival. 
As shown, NOD-like receptors 1 and 2 (NOD1, NOD2) are expressed in the pituitary 
gland and in AtT20 cells. Increased mRNA levels of NOD1 and NOD2 could be observed 
in a subset of human pituitary adenomas in comparison with normal pituitaries. In 
AtT20 cells and human pituitary adenomas, NOD1 ligand, diaminopimelic acid and 
NOD2 ligand, muramyl dipeptide, induced proliferation. In contrast, the proliferative 
effect of NOD ligands was abolished in AtT20 cells treated with PI3K/AKT inhibitors, 
LY294002 and Wortmannin, and NF-κB inhibitor CAPE (Caffeic acid phenethyl ester). 
Further, NOD ligands activated several components of the PI3K/AKT pathway in AtT20 
cells such as AKT, mTOR and p70S6K1. In contrast, they downregulated tumor 
suppressors such as PTEN, p27, p53 and BAX pro-apoptotic gene expression. Moreover, 
NOD ligands increased Cyclin D1, D3 and E protein expression. In the present study it is 
demonstrated that NOD activation promotes the survival of AtT20 cells through several 
signaling pathways. These findings provide a new insight into infection-associated 
tumorigenesis and illustrate the importance of immune receptors in the 
pathophysiology of pituitary tumoral cells. NOD receptors might be a new therapeutic 
target in the prevention of tumor progression.  
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1. Introduction 
1.1 The pituitary gland 
The pituitary gland is located at the base of the brain beneath the hypothalamus, and is 
no larger than a pea. It is an important component of the endocrine system, and together 
with the hypothalamus, exerts considerable inﬂuence over the functions of other 
endocrine glands. The hypothalamus either positively or negatively regulates hormonal 
production in the pituitary through its release of various hormones, which act on 
speciﬁc cell types in the pituitary to secrete a variety of pituitary hormones, which are 
important for growth and development, metabolism, reproductive and nervous system 
functions. The pituitary (Fig. 1) is composed of two different lobes: the anterior lobe or 
adenohypophysis, that derives embryologically from an evagination of the oral cavity 
(Rathke´s pouch), and the neuronal part also known as posterior lobe or 
neurohypophysis, derived by a downward extension of the hypothalamic area, which 
forms the hypophyseal stalk. Between the anterior and posterior lobes there is a third 
part, the intermediate lobe, which in rodents plays a significant role in the regulation of 
pigmentation, but in humans is reduced to a few cells without any known function.  
 
Fig. 1: The pituitary gland. The normal 
pituitary is a bean-shaped gland that has 
two components. The neurohypophysis, 
also known as the posterior lobe, is an 
extension of the hypothalamus. The 
adenohypophysis is composed of 
hormone-secreting epithelial cells, known 
as adenohypophysial cells, which are 
derived from the oral ectoderm and ascend 
as Rathke's pouch during development. 
The intermediate lobe, or pars intermedia, 
is composed of epithelial cells from the 
posterior limb of Rathke's pouch and is 
only rudimentary in humans.  
 
Copyright © Nature Reviews (Sylvia L. Asa & Shereen Ezzat, November 2002) 
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The anterior lobe produces the following hormones, which are regulated by the 
hypothalamus: 
 Growth hormone - GH promotes growth of the skeleton and soft tissues and has 
important metabolic effects. It acts directly on peripheral GH receptors or 
indirectly by inducing insulin-like growth factor I (IGF-I) synthesis in the liver. 
 Thyroid-stimulating hormone (TSH) - stimulates the thyroid gland to produce 
thyroid hormones. 
 Adrenocorticotropin hormone (ACTH) - ACTH induces glucocorticoid secretion 
from adrenal cortex and is a split product of proopiomelanocortin (POMC), a 
precursor protein from which also endorphins, encephalins, corticotropin-like 
immunoreactive peptides and melanocyte stimulating hormones are produced. 
 Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) - hormones 
that control sexual function and production of the sex steroids estrogen and 
progesterone in females or testosterone in males. 
 Prolactin - hormone that stimulates milk production in females. 
Generally, 50% of the cells are somatotropes, 10%–20% are lactotropes, 10%–20% are 
thyrotropes, 10%–20% are corticotropes and 10%–20% are gonadotropes [1]. The 
posterior lobe produces the following hormones, which are not regulated by the 
hypothalamus: 
 Antidiuretic hormone (vasopressin) - controls water loss by the kidneys. 
 Oxytocin - contracts the uterus during childbirth and stimulates milk production. 
The hormones secreted by the posterior pituitary are actually produced in the brain and 
carried to the pituitary gland through nerves where they are stored.  
1.2 Pituitary tumor cells AtT20 and their endocrine applications 
This cell line was established by alternatively passaging ACTH-producing mouse 
pituitary tumors in culture and in animals [2]. ACTH-producing tumor cells were ﬁrst 
dispersed and cultured, and after various periods in culture, were injected into mice to 
obtain new tumors. New tumors which still produced ACTH were then put back into 
culture, and the process repeated to select cell lines that are able to produce ACTH and 
grow in culture permanently [3]. Like the corticotropes in the anterior pituitary, AtT20 
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cells synthesize POMC, the precursor to ACTH and endorphins, and correctly process it 
to the mature forms of the hormones before they are secreted. Consequently, this cell 
line was used extensively to study the processing of POMC and how this process is 
regulated by glucocorticoids and cytokines [4-11]. Corticotropin releasing hormone 
(CRH), vasoactive intestinal polypeptide (VIP), phorbol ester, forskolin, IL-1 and IL-6 
regulate the secretion of ACTH and β-endorphin from the AtT20 mouse pituitary cell line 
[12-13]. AtT20 cells express glucocorticoid receptors [14-18], somatostatin receptors 
[19], interleukin-1 receptors [20-22], high affinity histamine H3 receptors [23-24], 
dopamine receptors [25-27], as well as muscarinic cholinergic receptors [28-30], all of 
which can regulate ACTH release.  
1.3 Tumor development and cell cycle – a general overview 
1.3.1 Tumor development 
Cancer is a hyperproliferative disorder that involves morphological cellular 
transformation, dysregulation of apoptosis, uncontrolled cellular proliferation, invasion, 
angiogenesis and metastasis. Clinical and epidemiologic studies have suggested a strong 
association between chronic infection, inflammation and cancer. The vast majority of 
cancer cells harbor six common properties that are essential for the transformation of a 
normal cell into a malignant phenotype [31]. The acquired capabilities, such as self-
sufficiency in growth-signals, insensitivity to anti-growth signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis, mediate the successful breakage of the pre-existing anticancer 
defense mechanism of the organism. These changes involve activation of oncogenes and 
inactivation of tumor suppressors, leading to an imbalance between pro- and anti-
growth signaling [32]. Tumor development and growth are thought to be the outcome of 
a series of different mutations occurring in a somatic cell, leading to progressive 
acquisition of proliferative advantage compared to non-mutated cells. These mutations 
can affect different genes essential for cell survival, belonging to two major categories: 
proto-oncogenes and tumor suppressor genes. Proto-oncogenes have an important role 
in the regulation of cell proliferation, differentiation and apoptosis. They usually act as 
positive regulators of cell growth and in cancer they can be activated by gain of function 
point mutations, overexpression because of gene amplification, translocation of the 
4 
 
proto-oncogene in an area of actively transcribed chromatin, increase in promoter 
activity or protein stability. On the other hand, tumor suppressor genes inhibit cell 
proliferation and are mostly involved in the inhibition of cell cycle progression, 
induction of cell differentiation and programmed cell death and in the assembly of the 
mitotic machinery. They acquire transforming potential by losing their anti-proliferative 
properties. This can be due to loss of function mutations, loss of a big chromosomic 
portion or to epigenetic alterations like hypermethylation of cytosine-guanine 
dinucleotides in promoters with consequent gene silencing [33]. 
Pituitary adenomas 
Pituitary adenomas are benign neoplasms, accounting for approximately 15% of 
intracranial tumors. An occult adenoma is discovered in about 25% of unselected 
autopsies. Pituitary tumors are usually benign and do not metastasize, although some of 
them can become invasive, leading to bone destruction and infiltration within the 
cavernous sinus. They can cause severe clinical symptoms due to their critical location 
and expanding size, like headache and visual disorders, and to inappropriate pituitary 
hormone production. The clinical features associated with hormonal hypersecretion 
reflect specifically the type of endocrine cell from which the adenoma arises. Therefore, 
ACTH oversecretion results in Cushing disease with features of hypercortisolism, GH 
hypersecretion leads to acral overgrowth and metabolic dysfunction associated with 
acromegaly and PRL hypersecretion leads to gonadal failure, secondary infertility and 
galactorrhea. More rarely, TSH hypersecretion leads to hyperthyroxinemia and goiter, 
and hypersecreted gonadotropins lead to gonadal dysfunction. Non functioning pituitary 
adenomas (NFPA), also known as hormone inactive, do not secrete hormones and 
therefore have no typical hormone excess-related presentation. An overview of the 
secreted hormones of the pituitary gland and the pituitary adenomas is given in figure 2.  
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Fig. 2: Hypothalamic-pituitary regulation and pituitary tumor pathogenesis 
 
Pituitary tumor development results from both intrinsic alterations of the pituitary 
gland cells and from dysregulation of regulatory factors like hypothalamic releasing and 
inhibitory hormones, peripheral hormones and paracrine growth factors. There are two 
main theories discussed about pituitary tumor genesis. According to one theory, 
adenomas arise from a mutational transforming event in a single cell that then will 
proliferate under the effect of hormones and growth factors, originating a monoclonal 
tumor. The second theory posits that hypothalamic hormones and growth factors induce 
pituitary hyperplasia, in which a mutational event in a hyperplastic cell will lead to 
tumor formation. Overexpressed oncogenes described in pituitary tumorgenesis are: G 
proteins [34-35], Cyclin D1 [36] and growth factors and their receptors [37-40]. Tumor 
suppressor genes lost or dysregulated in pituitary adenomas include: MEN-1 encoding 
the protein menin [41], Rb [42-43], p16 [44], p27 [45], and Zac 15 encoding a zinc finger 
transcription factor [46].  
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1.3.2 Cell cycle 
Tumor-associated mutations in many of these molecules result in the alteration of the 
basic regulatory mechanisms that control the mammalian cell cycle. Cell cycle 
dysregulation can lead to uncontrolled cell proliferation and consequently to tumor 
development. The basic cell cycle is divided into four phases (Fig. 3). During two of these 
phases, cells execute the two basic events in cell division: generation of a single and 
faithful copy of its genetic material (the synthetic or S phase) and partitioning of all the 
cellular components between two identical daughter cells (mitosis or M phase). The two 
other phases of the cycle — G1 and G2 — represent ‘gap’ periods, during which cells 
prepare themselves for the successful completion of the S and M phases, respectively. 
When cells halt proliferation, either due to specific antimitogenic signals or to the 
absence of proper mitogenic signaling, they exit the cycle and enter a non-dividing, 
quiescent state known as G0.  
 
To ensure proper progression through the cell cycle, cells have developed a series of 
checkpoints that prevent them from entering into a new phase until they have 
successfully completed the previous one [47]. It is obvious that newly divided or 
quiescent cells must also pass certain checkpoints before they can enter the cycle. For 
instance, cells must make sure that they have reached their homeostatic size, otherwise 
cells will become smaller with each round of division. The genetic elements that control 
Copyright ©The Science Creative Quarterly (scq.ubc.ca) Jane Wang 
Fig. 3: The basic cell cycle 
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these parameters remain largely unknown. However, they can be influenced by external 
elements, such as the amount of available nutrients or the intensity of the mitogenic 
stimulation that cells receive at any given time. Indeed, these two parameters are key 
determinants for cell division. For instance, if cells have mitogenic requirements that are 
too stringent, they might not be able to proliferate at crucial times, such as during 
wound healing or during an infection. Conversely, loosening these controls might lead to 
unscheduled proliferation and possibly neoplastic growth. In culture, cells undergo a 
period of mitogen dependence before they enter the cycle. This transition — the 
Restriction Point (R) — represents a point of no return that commits cells to a new 
round of cell division [48]. 
The cyclin-dependent kinases (CDKs), the cyclin-dependent kinase inhibitors (CKIs) 
and their molecular regulators 
Cyclin-dependent kinases are heterodimeric enzymes with a protein kinase subunit and 
a cyclin subunit that are regulated by various chemical changes. The kinase is 
completely inactive without its cyclin partner, but in addition to the binding of the 
cyclin, activation of the holoenzyme requires the phosphorylation of a key residue in the 
activation loop of the kinase subunit [49]. An overview of the CDKs and its cyclin 
partners and how they are regulated is given in figures 4 and 5. By binding, the CDK gets 
phosphorylated and activates or inactivates target proteins to coordinate entry into the 
next phase.  
 
Fig. 4: CDKs and its cyclin partners 
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Fig. 5: Regulation of G1 phase and G1/S transition. In quiescent G0 cells, E2F–DP transcription 
factors are bound to p130, the principal pocket protein in these cells, which keeps them inactive. 
Mitogenic signaling results in Cyclin D synthesis, formation of active CDK4/6–Cyclin D complexes 
and initial phosphorylation of Rb. Partially phosphorylated Rb still binds to E2F–DP, but the 
transcription factor is already able to transcribe some genes, such as Cyclin E, which in turn binds 
to and activates CDK2. It is generally accepted that CDK2-dependent phosphorylation of Rb 
results in its complete inactivation, which allows induction of the E2F-responsive genes that are 
needed to drive cells through the G1/S transition and to initiate DNA replication.  
 
The most important restriction point in mammalian cells is in G1 phase. During the early 
G1 phase and after receiving a mitogenic signal, the Cyclin D, which is the first cyclin 
produced in the cell cycle, binds to CDK4 and this complex phosphorylates 
retinoblastoma protein Rb. Rb activates E2F, which finally will lead to the transcription 
of various genes like Cyclin E; Cyclin E forms a complex with CDK2 and pushes the cell 
from G1 to S phase. So, according to the classical view Cyclin E – CDK2 is required to 
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initiate S phase [50]. The negative control on cell cycle progression is exerted by the 
cyclin-dependent kinase inhibitors (CKIs), which bind to CDK and inhibit their activity 
[51]. The members of the INK family (p16, p15, p19) inhibit CDK 4/6 in the early G1 
phase [52], whereas members of the WAF/KIP family (p21, p27, p57) inhibit CDK2 
activity in the late G1 phase [53]. 
CDK`s are regulated by phosphorylation on threonin residue for proper catalytic activity 
[54]. The D-type cyclins are important integrators of mitogenic signaling, as their 
synthesis is one of the main end points of the MAPK pathway. Cyclin D1 is a rather 
unstable molecule, which is transported from the nucleus to the cytoplasm where it is 
targeted for proteolysis. Nuclear export is mediated by GSK-3β (glycogen synthase 
kinase-3β), a kinase that is inhibited by the PI3K/AKT pathway. So, the Cyclin-D1 
availability is controlled by a balance between the MAPK (Cyclin-D1 synthesis) on the 
one hand, and PI3K/AKT (cyclin-D1 stability) pathways, as well as by GSK-3 β (Cyclin-
D1 degradation), on the other. [55-56]. 
The primary substrates for CDK4/6 and CDK2 in G1 progression are the members of the 
retinoblastoma protein family Rb, p107 and p130 [57]. These molecules function as 
docking sites for a series of proteins that must be tightly regulated throughout the cell 
cycle. For instance, Rb proteins bind to E2F family of transcription factors to ensure that 
they remain inactive during M and G0 phase. In addition Rb-E2F complexes participate 
in active repression of some promoters, a mechanism that involves other protein 
families. The activity of the Rb proteins can be modulated by phosphorylation by CDK4-
Cyclin-D and CDK2-Cyclin-E complexes [58]. Hyper-phosphorylated Rb proteins release 
the molecules that bind to their hypophosphorylated isoforms, allowing them to carry 
out their specific tasks in cell cycle progression.  
1.3.3 How tumor suppressors and their companions affect tumor development 
Tumor suppressor genes, such as p53 and PTEN, are genes whose products protect the 
cell from taking the path to cancer. They suppress malignant transformation by 
regulating cell cycle progression, ensuring the fidelity of DNA replication and 
chromosomal segregation, or by inducing apoptosis. These transcription factors are 
induced by oncogenes, DNA damage and other stress signals. 
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The role of p53 as a tumor suppressor is generally attributed to its ability to stop the 
proliferation of precancerous cells by inducing cell cycle arrest or apoptosis. So, it exerts 
influence on the decision whether the cell could live or has to die [59]. The p53 function 
is disrupted by mutations in about 50% of all human tumors, and in the other half the 
p53 protein is inactivated by various cellular antagonists. In fact, alterations in p53 
function are the most frequent genetic event found in a broad range of human tumors 
[60]. p53 activates genes which are crucial for the execution of pathways leading to 
survival or apoptosis such as the members of the BCL-2 family, which includes both, pro-
apoptotic proteins like BAX and anti-apoptotic proteins like BCL-2. In this context p53 is 
shown to physically interact with pro-apoptotic factors like BAX and inhibits survival 
signals like BCL-2 [61]. p21 is the most famous p53-induced cell cycle inhibitory gene 
that can induce G1 and G2 arrest, by inhibiting Cyclin E/CDK2 and Cyclin B/CDK1. When 
p21 is complexed with CDK2, the cell cannot pass through the next stage of cell division. 
Furthermore, upon induction, p21 inhibits Cyclin E/CDK2 causing hypophosphorylation 
of Rb that binds E2F to inhibit E2F-mediated transcription of cell cycle genes [62].  
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor 
suppressor gene and is both a protein and lipid phosphatase [63-65]. It is one of the 
most commonly lost tumor suppressors in human cancer and controls multiple cellular 
functions such as cell metabolism, proliferation, cell cycle progression and survival. The 
phosphatase domain has homology to protein tyrosine phosphatases, dual-specificity 
phosphatases and to tensin and auxilin. This phosphatase is involved in cell cycle 
regulation, preventing the cells from growing and dividing too rapidly by negatively 
regulating the PI3K/AKT signaling pathway [66-68]. The lipid phosphatase activity of 
PTEN can dephosphorylate the D3 position of PtdIns-3,4-P2 and PtdIns-3,4,5-P3, the 
lipid products of the PI3K lipid kinase activity [69]. Thus, PTEN antagonizes signaling 
through the PI3K pathway. Indeed, cells lacking PTEN function exhibit a two fold 
increase in PtdIns-3,4,5-P3 levels [70-71]. One of the positive regulators of PTEN 
promoter activity is p53 and one of the negative regulators is NF-κB, which has been 
shown to inhibit PTEN protein expression in several cancers [72-73]. 
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1.4 Innate immunity and cancer 
The innate immune system provides a rapid response to pathogens, and in contrast to 
the adaptive immune system, is constitutively activated. It does not require the 
existence of cells with memory. Such an immediate activation of innate immunity relies 
on the detection of conserved microbial motifs by the host, known as pathogen-
associated molecular patterns (PAMPs), a diverse family of molecules including 
lipopolysaccharide, peptidoglycan, bacterial lipoproteins, flagellin and nucleic acid 
structures from bacteria and viruses. PAMPs are recognized by specific receptors of the 
innate immune system. Categorically, three PRRs (pathogen recognition receptors) 
types are known. Extracellular complement, transmembrane TLRs (toll-like receptors) 
and intracellular NOD (nucleotide oligomerization domain) proteins. After sensing the 
presence of a PAMP, host innate immune cells initiate a broad spectrum of defense 
mechanisms that result in the development of inflammation and host resistance to 
infection: the recruitment of professional phagocytes, the release of antimicrobial 
peptides and the establishment of a network of cytokines, chemokines and prostanoids 
[74]. The main purpose of these effects is to kill invading organisms. However, 
inadequate elimination, prolonged inflammatory signaling and defects in anti-
inflammatory responses can all lead to chronic inflammation and benefit tumor 
development [75].  
It is already known that chronic inflammation is involved in tumor initiation (the 
process by which normal cells are genetically altered so that they become malignant), 
promotion (the process by which small clusters of malignant cells are stimulated to 
grow) and progression (the process by which the growing tumor becomes more 
aggressive). For instance, da Silva Correia et al. showed in MCF-7 cells a mechanism that 
links innate immunity and tumor growth [76]. Another paper showed the participation 
of NOD1 in the regulation of colitis-associated colon tumorigenesis [77]. Moreover, 
Cruickshank et al. could show the involvement of NOD2 in regulating growth and 
survival of colorectal carcinoma cell lines [78]. In a previous study, our group showed 
that the transmembrane TLR4 was found not only in immune but also in non-immune 
cells including normal pituitary cells, and that their activation affected pituitary tumor 
pathophysiology and progression [79]. Moreover we could recently show the expression 
of NOD receptors in folliculostellate TtT/GF cells of the anterior pituitary. The results 
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obtained in that study showed that TLR4 and NOD receptors act in synergy to activate 
certain events [80]. During my diploma thesis, which was focused on TtT/GF cells, I 
started to examine the expression of NOD receptors in pituitary adenoma. Although 
much attention has been paid in recent years to the interaction between host and 
pathogen, direct interaction between bacteria and tumor cells has been largely 
overlooked. Nevertheless, it is still unclear how bacteria interact with tumor cells and 
how the consequences of such interactions influence tumor progression and 
immunotherapy. 
1.4.1 NOD-like receptor family 
In humans, the NLR (NOD-like receptor) family is composed of 22 proteins, and there 
are at least 33 NLR genes in mice. Although primarily expressed in immune cells 
including both lymphocytes and APCs (antigen-presenting cells) such as macrophages 
and dendritic cells, NLRs can also be expressed in non-immune cells, including epithelial 
and mesothelial cells. This family of proteins is deﬁned by a tripartite structure (Fig. 6) 
consisting of a variable N-terminal protein-protein interaction domain, deﬁned by a 
CARD (caspase recruitment domain) domain, a central NOD (nucleotide oligomerization 
domain) domain, which mediates self-oligomerization that occurs during activation, and 
LRRs (C-terminal leucine-rich repeats), that detects PAMPs [81].  
 
Fig. 6: Structure of NOD proteins. The general structure consists of C-terminal LRRs, a centrally located 
NOD domain and one or two CARD effector domains. 
 
The N-terminal domain of the NLRs is critical for downstream signaling. CARD domains 
were originally associated with proteins involved in apoptosis and inﬂammation such as 
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many of the caspases, including caspase-1. However, CARDs have also been shown to 
mediate caspase-independent interactions. CARD possessing proteins are members of 
the death domain–fold superfamily, members which are involved in both apoptosis and 
inflammation [82]. Three major activation targets of NOD proteins have been identified: 
NF-κB, MAPK and Caspase-1 [83-84].  
NOD1 (which is encoded by the caspase-recruitment domain 4 gene, CARD4) and NOD2 
(which is encoded by CARD15) recognize PGN (peptidoglycan), a component of bacterial 
cell walls. NOD1 recognizes the dipeptide iE-DAP (γ-D-glutamyl-meso-diaminopimelic) 
acid, whereas NOD2 recognizes MDP (muramyl dipeptide) [85-86]. As PGN from both, 
Gram-positive and Gram-negative bacteria contains MDP, NOD2 functions a general 
sensor of bacteria. Because PGN from Gram-positive bacteria do not contain iE-DAP, 
NOD1 mainly senses products of Gram-negative bacteria [86-87]. Both NOD1 and NOD2 
can be auto-activated upon overexpression. Overexpression of these molecules leads to 
auto-oligomerization through the NBS (nucleotide-binding site) region [88].  
NOD receptor signaling 
NOD1 and NOD2 are responsible for the activation of both the NF-κB (nuclear factor 
kappa B) and the MAPK (mitogen-activated protein kinase) pathways [89]. Upon 
recognition of their respective agonists, both NOD1 and NOD2 self-oligomerize to recruit 
and activate the adaptor protein RICK (receptor interacting protein-like interacting 
caspase-like apoptosis regulatory protein kinase), which is essential for the activation of 
both NF-κB (Fig. 7) and the MAPKs [90-91]. RICK (also known as RIP2) is a CARD-
containing kinase and becomes polyubiquitinated upon interaction with NOD1 or NOD2 
through homotypic CARD-CARD interactions. The RICK ubiquitination step is essential 
for recruitment of the kinase TAK1 (TGFβ-activated protein kinase 1), which activates 
the NF-κB-activating complex [92].   
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Fig. 7: NOD proteins mediated NF-κB activation. NOD receptor activation through their 
ligands iE-DAP and MDP recruits the adapter molecule RICK, which in turn recruits the 
TAK1 kinase. Activation of the IKK complex (NEMO, IKKα and IKKβ) phosphorylates the 
inhibitory protein IκBα, which leads to its proteosomal degradation; thus, liberating NF-κB 
dimers and allowing them to regulate gene transcription in the nucleus. 
 
The colocalization of NEMO (NF-κB essential modulator) and TAK1 results in the 
phosphorylation and degradation of IκBα and finally to the nuclear translocation of NF-
κB [93]. Further details on NF-κB activation will be given in chapter 1.5.1. NF-κB 
subsequently activates transcription of inﬂammatory cytokines and chemokines such as 
TNF-α, IL-6 and IL-8, which are important for stimulation and recruitment of additional 
effector cells during host defense. NF-κB is also involved in proliferation and in the 
regulation of members of the BCL-2 family, which consist pro-apoptotic and anti-
apoptotic proteins. 
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1.4.2 NOD proteins in diseases and cancers – an overview 
Different mutations of NOD2 can lead to decreased or increased NF-κB activity, causing 
two distinct phenotypes. While gain of function mutations have been associated with BS 
(Blau Syndrome), other mutations considered to be loss of function have been 
associated with Crohn`s Disease (CD). The mutation in case of Blau Syndrome is said to 
be located in the NOD domain, while the mutation causing Crohn`s Disease is located in 
the LRR domain. Most epithelial cells constitutively express NOD1, whereas NOD2 is 
restricted to Paneth cells – secretory epithelial cells located at the base of intestinal 
crypts. They secrete antibacterial substances, initially located in granules within the 
cytosol, in response to prokaryotic rather than eukaryotic pathogens. The main 
antimicrobial factors secreted by the Paneth cell include lysozyme, phospholipase A2, 
trypsin, α-defensins and agiogenins. NOD2 expression is located in close proximity to 
the secretory granules. Indeed, this close proximity prompts speculation that NOD2 may 
be involved in degranulation and mediator release. As the mutation in the case of 
Crohn`s Disease is located in the LRR region, these cells have a decreased NF-κB 
response to MDP. Therefore, impairing NF-κB response and production of α-defensins, 
that normally keeps the commensal bacterial population downregulated, leads to 
overgrowth of the intestinal microflora and increased susceptibility to enteric 
pathogens, triggering an adaptive immunity hyper-responsiveness that causes and 
maintains inflammation [94].  
Abnormalities in the normal function of NOD1 can lead to development of chronic 
infection with helicobacter pylori and to the subsequent development of peptic-ulcer 
disease and gastric carcinoma [95-96]. It has been shown that variation in the NOD1 
gene is correlated with the development of asthma, as the NOD1 gene is located in a 
region which genetically has been linked to asthma [97].  
To summarize, NOD proteins are excellent examples of the crosstalk between innate 
immunity and control of inflammation. Physiologically, NOD proteins are involved in 
intracellular sensing of bacterial components, but when dysregulated, they lead to 
inflammatory diseases and to the development of cancers. 
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1.5 Participating signaling pathways 
1.5.1 NF-κB (nuclear factor kappa B) 
One transcription factor that serves as a key responder to changes in the cells` 
environment is NF-κB, an evolutionarily conserved signaling pathway that plays a 
critical role in many biological processes. The five members of the mammalian NF-κB 
family, p65 (RelA), RelB, c-Rel, p50/p105 (NF-κB1) and p52/p100 (NF-κB2), exist in 
unstimulated cells as homo- or heterodimers bound to IκB family proteins. NF-κB 
proteins are characterized by the presence of a conserved 300-amino acid Rel homology 
domain (RHD), which is located toward the N terminus of the protein and is responsible 
for dimerization, interaction with IκBs and binding to DNA. The cascade of NF-κB 
activation by NOD signaling is depicted in figure 8.  
 
Fig. 8: Schematic representation 
of the NF-κB pathway activation. 
NOD signaling activates the IKK 
complex, which phosphorylates 
the inhibitory IκBα protein, 
triggering its subsequent 
ubiquitination and degradation 
by the proteasome (IKK 
Complex). Removal of IκBα 
enables newly freed NF-κB 
dimers to undergo post 
translational modification, such 
as p65 phosphorylation, and 
translocate to the nucleus. They 
bind to their specific DNA 
element and ultimately activate 
transcription of target genes.  
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NF-κB transcription factors stand out as master regulators of innate and adaptive 
immunity and inflammation [98]. NF-κB also promotes cell survival, and this activity is 
crucial for antagonism of programmed cell death, tumorigenesis and chemoresistance in 
cancer. Indeed, whereas NF-κB contributes to many aspects of oncogenesis, including 
cell proliferation, tissue invasiveness, angiogenesis and metastasis formation, it is now 
clear that its suppressive action on apoptosis is central to this process [99].  
Recent studies have put new light on the basis for this pivotal role of NF-κB in 
carcinogenesis. One common event in cancer is inflammation, and indeed, chronic 
infections and inflammation account for 15–20% of all cancer deaths in humans. 
Notably, it was shown that a crucial link between inflammation and carcinogenesis 
depends on NF-κB – documented in both, humans and animal models. In this link NF-κB 
promotes synthesis of inflammatory mediators, such as TNFα, that potently stimulate 
growth of cancer cells, and upregulates genes that protect these cells against 
programmed cell death induced by proinflammatory signals [100-101]. 
1.5.2 MAPKs (mitogen-activated protein kinases) 
The MAPKs are one of nature’s preferred “solutions” for signaling, and the basic three-
kinase module (Fig. 9) has been replicated for various tasks in all eukaryotes.  
 
Fig. 9: MAPK modules. 
These pathways respond 
cellular signals including 
growth factors, hormones 
and cell stress cytokines. 
Once activated, MAPKs 
can phosphorylate a wide 
range of proteins, 
including transcription 
factors and other kinases 
[102]. 
Copyright © Cell Signaling Technology® 
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While the overall structure of the module is remarkably conserved, the inputs and 
outputs are diverse. MAPKs are now commonly used as examples of an entire class of 
protein serine kinases that share several key features, including regulation by tyrosine 
and threonine phosphorylation and organization into a hierarchical cascade of kinases. 
Upon stimulatory effects the MAPKKKs come into close proximity to the MAPKK and 
appropriate MAPK, thus leading ultimately to MAPK phosphorylation and activation. 
Once stimulated the MAPK can then bind and stimulate other kinase targets, translocate 
to the nucleus to activate gene transcription or induce other actions [103]. These MAPK 
pathways are essential for processes such as gene expression, mitosis, differentiation, 
proliferation, cell survival and apoptosis [104]. To date, the sequences of over 100 
eukaryotic MAPKs have been reported. In mammals, three major MAPK signaling 
modules have been described: the original MAPK or ERK (extracellular signal-regulated 
kinase) and two MAPK cascades that respond to cellular stresses, JNKs (SAPK or c-Jun 
NH2-terminal kinase) and P38 MAPKs [105]. 
The ERK (extracellular signal-regulated kinase) Kinase 
In mammals, the prototypical MAPKs are encoded by two genes, ERK-1 and -2, 
generating proteins of 44 kDa and 42 kDa, respectively. Like most of the MAPK proteins, 
these enzymes are widely expressed and are generally not regulated at the 
transcriptional level. These enzymes are phosphorylated and activated by MAPK/ERK 
kinases (MEKs) 1 and 2 [106]. ERK activation is often associated with proliferation, but 
consequences of ERK stimulation depends on the signal and cell type. Even in the same 
cell type, the kinetics of ERK activation play a defining role in the ultimate response. 
Thus, the same signaling machinery can deliver different messages within a cell. The 
signaling pathways which the members of these families inﬂuence, can be independent 
of each other, or overlapping [107]. 
JNKs (c-Jun N-terminal kinase) 
While the ERK family of MAPKs is primarily activated by growth factors and mitogens, 
the JNK and P38 MAPK families are preferentially induced by stress signals including 
irradiation, pro-inflammatory cytokines, environmental stress and other circumstances 
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important for the cellular environment. The JNKs consist of ten isoforms derived from 
three genes (JNK2, JNK3 and JNK1), that encode 54 kDa or 46 kDa proteins [108]. The 
JNKs were originally identified as the major serine/threonine kinases responsible for 
the phosphorylation of c-Jun, a component of the AP-1 transcription factor [109]. The 
activated JNKs mostly target transcription factors. The general consequence of chronic 
JNK signaling is induction of apoptosis. 
P38 MAPK 
The P38 MAPK group consists of four members: P38α, P38β, P38γ and P38δ. These 
proteins are encoded by separate genes and are approximately 60% identical at the 
amino acid level. The P38 MAPKs affect a variety of intracellular responses with well-
recognized roles in inflammation, cell death, development, differentiation, senescence 
and tumorigenesis [110]. Recently it has been shown that P38 is involved in the 
regulation of cell cycle and the initiation of cell cycle checkpoints to mediate cell survival 
[111].  
1.5.3 PI3K (Phosphoinositide 3-kinases)/AKT pathway  
The family of lipid kinases named PI3Ks (phosphoinositide 3-kinases) has been found to 
have key regulatory roles in many cellular processes including cell survival, proliferation 
and differentiation [112]. As major effectors downstream of receptor tyrosine kinases 
(RTKs) and G-protein-coupled receptors (GPCRs), PI3Ks transduce signals from various 
growth factors and cytokines into intracellular messages by generating phospholipids, 
which activate the serine-threonine protein kinase AKT (also known as protein kinase B, 
PKB) and other downstream effector pathways. PI3Ks are divided into three enzyme 
classes, according to their structural characteristics and substrate specificity [113]. The 
most commonly studied ones are the class I enzymes, that are activated directly by cell 
surface receptors. They are further divided into class IA, which are activated by RTKs, 
GPCRs and certain oncogenes, and class IB, which are regulated exclusively by GPCRs. 
Signaling through this pathway can start from binding of growth factor with its receptor. 
The activated receptors undergo auto-phosphorylation and acquire tyrosine kinase 
activity. The activator and the PI3 kinase then activates PI(4,5)P2 into 
phosphatidylinositol-3,4,5-triphosphate PI(3,4,5)P3, which can be reversed by PTEN, 
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which acts as an antagonist. PDK-1/2 and AKT are recruited to the plasma membrane by 
binding to PI (3,4,5) P3 via their pleckstrin homology (PH) domains. After localization to 
the membrane, PDK-1/2 is able to activate AKT by phosphorylation at Thr 308 and Ser 
473. Activated AKT subsequently phosphorylates many downstream proteins. A 
summary of PI3K/AKT pathway activation and their targets is depicted in figure 10.  
The serine-threonine protein kinase AKT mediates many of the downstream effects of 
PI3K and consequently plays a central role in both normal and pathological signaling by 
the PI3K pathway. There are three closely related enzymatic isoforms AKT1 (PKBα), 
AKT2 (PKBβ) and AKT3 (PKBγ), encoded by three different genes located on 
chromosomes 14q32, 19q13 and 1q43, respectively. They are similar in both, structure 
and size, and are thought to be activated by a common mechanism [114]. AKT has 
additional effects on tumor-induced angiogenesis that is mediated, in part, through HIF-
1α (hypoxia-inducible factor-1α) and VEGF (vascular endothelial growth factor). The 
main biological consequences of AKT activation, which are relevant to cancer-cell 
growth, can be catalogued loosely into three categories — survival, proliferation 
(increased cell number) and growth (increased cell size). These three categories will be 
discussed more extensively in the following paragraphs and are also depicted in figure 
10. 
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Fig. 10: PI3K/AKT pathway and its influence on downstream proteins 
 
Survival versus Apoptosis  
Apoptosis, or programmed cell death, is a normal cellular function that controls 
excessive proliferation by eliminating ‘unnecessary’ cells. Cancer cells have devised 
several mechanisms to inhibit apoptosis and prolong their survival. AKT functions in an 
anti-apoptotic manner. Among the many substrates of AKT, BAD proteins dissociate 
from BCL-2 or BCL-XL and lose the ability to induce apoptosis [115]. AKT can also 
influence cell survival by means of indirect effects on two central regulators of cell 
death, the transcription factor NF-κB and p53. AKT can exert a positive effect on NF-κB 
function by phosphorylation and activation of IKK (IκB kinase), the kinase that induces 
degradation of the NF-κB inhibitor, IκB, and therefore allowing nuclear translocation 
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and activation of target genes [116]. Furthermore, AKT can also influence the activity of 
the pro-apoptotic tumor suppressor p53 through phosphorylation of the p53-binding 
protein MDM2. MDM2 is a negative regulator of p53 function that targets p53 for 
degradation by the proteasome. Two recent studies provide a new mode of MDM2 
regulation through phosphorylation by AKT. Phosphorylated MDM2 translocates more 
efficiently to the nucleus, where it can bind p53, resulting in enhanced p53 degradation 
[117]. AKT is also known to inactivate FOXO, which regulates transcription of pro-
apoptotic proteins such as Fas-ligand (FasL) and Bim [112].  
Proliferation 
AKT also controls cell cycle progression by inactivating p27 and GSK-3ß (glycogen 
synthase kinase-3ß). p27, a cyclin-dependent kinase inhibitor, and GSK-3ß play roles in 
the induction of cell cycle arrest. Phosphorylated p27 is translocated from the nucleus, 
the site of its activity, to the cytoplasm where it is degraded. In case of GSK-3ß, 
phosphorylation causes the loss of its kinase activity, thereby supporting the cellular 
growth response to growth factor stimulation. AKT promotes the G1-S phase transition 
by blocking FOXO mediated transcription of cell cycle inhibitors, including p27, or 
directly phosphorylates and inactivates p27, as mentioned before [112]. 
Cell growth 
In addition to its role in proliferation and survival, there is evidence that AKT also affects 
cell growth. Proliferation refers to cell division, which leads to an increase in cell 
number, whereas growth refers to the synthesis of macromolecules, which results in 
increased cell mass or size, a process that is enhanced in cancer cells. One protein that is 
a central regulator of cell growth is mTOR (the mammalian target of rapamycin,), a 
serine/threonine kinase that serves as a molecular sensor, which regulates protein 
synthesis on the basis of the availability of nutrients. mTOR regulates biogenesis by 
activating p70S6 kinase [118].  
There is already evidence that at least NOD2 signaling has an impact on the PI3K/AKT 
pathway and its components [119]. A lot of evidence has implicated aberrations in the 
PI3K/AKT pathway in tumorigenesis. The signaling elements of this pathway are found 
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to be highly activated and dysregulated due to overexpression, truncation or mutation in 
certain cancer types. Alterations in the PI3K/AKT pathway can lead to abnormal cell 
functions such as proliferation, differentiation, survival and migration. The accumulation 
of such uncontrolled cell signaling facilitates the formation of cancer [120].  
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2. Aim of the study 
 
The previous chapters presented some aspects of NOD signaling and its potential 
involvement in the regulation of cell survival, proliferation, cell growth and invasion. 
Nevertheless, the understanding of the network of interactions between the various 
factors that determine proliferation, survival or death, remains limited. Proteins which, 
up to now, have not been recognized to play a role in this machinery may eventually 
prove to be missing links in the pathways involved. 
There is a large body of evidence suggesting that innate immune receptors activation 
plays a role in tumor growth and development. To better understand how NOD proteins 
are involved in regulating proliferation, survival and apoptosis, it is particularly 
important to know more about the properties of these new intracellular proteins NOD1 
and NOD2. In this context, the main goal of this dissertation was to determine the 
expression and effects of innate immune receptors NOD1/2 signaling pathways in 
endocrine pituitary cells and pituitary adenomas.  
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3. Materials & Methods 
3.1 Materials 
3.1.1 Equipment 
Analytic Balance 1601 MP8  Sartorius AG (Göttingen, Germany) 
Cell culture bottles Nunc (Denmark) 
Cell culture incubator Cytoperm 8080 Heraeus GmbH (Hanau, Germany) 
Cell culture plates Nunc (Denmark) 
Cell scraper Renner (Dennstadt, Germany) 
Centrifuge Sepatech Varifuge 3 Haraeus GmBH (Osterode, Germany) 
Centrifuge Tubes Falcon (Heidelberg, Germany) 
ECL Western Blotting Detection System Amersham Biosciences (Uppsala, Sweden) 
ELISA – plate reader Dynatech MR 5000 Dynatech (Denkendorf, Germany) 
Phase Lock Gel Heavy Tubes 5 Prime GmbH (Hamburg, Germany) 
Laminar Flow Typ UVF 6.18 S BDK Luft und Reinraumtechnik GmbH 
(Sonnenbühl, Germany) 
TriStar LB 941 Berthold Technologies (Tennessee, USA) 
Microscope Axiskop 2 Carl Zeiss AG (Jena, Germany) 
Neubauer counting chamber, Blaubrand® BRAND GMBH + CO KG (Wertheim, 
Germany) 
Novex® Semi Dry Blotter Invitrogen Corp. (Paisley, UK) 
Pipettes Eppendorf (Hamburg, Germany) 
PVDF (Polyvinylidene fluoride) 
membranes 
Millipore Corp. (Bedford, MA, USA) 
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Shaker Scientific Industries Vortex- 
Genie®-2 
Scientific Industries Inc. (New York, USA) 
Spectrophotometer Beckman DU-640 Beckman Instruments Inc. (Miami, FL, 
USA) 
Eppendorf Table Centrifuge 5415R Eppendorf (Hamburg, Germany) 
Thermocycler- Techgene Labtech International (East Sussex, UK) 
Tris-Glycine 10% gel Anamed (Groß-Bieberau, Germany) 
Water bath Köttermann Labortechnik (Uetze-
Hänigsen, Germany) 
XCell SureLock™ Mini-Cell Invitrogen Corp. (Paisley, UK) 
 
3.1.2 Reagents 
ABC kit Vector Laboratories (Burlingane, CA, USA) 
Acridine orange Sigma (St. Louis, MO, USA) 
BSA (Bovine serum albumin) Sigma (St. Louis, MO, USA) 
Cell lysis buffer Promega Corp. (Madison, USA) 
Chloroform Sigma (St. Louis, MO, USA) 
Collagenase Worthington Biochemical Corp. 
(Lakewood, NJ, USA) 
Developer Solution Kodak (Stuttgart, Germany) 
Diaminobenzidine (DAB) Sigma (St. Louis, MO, USA) 
Diethyl-pyrocarbonate (DEPC) Sigma (St. Louis, MO, USA) 
Dimethylsulfoxid (DMSO) Sigma (St. Louis, MO, USA) 
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Dithiothreitol (DTT) Sigma (St. Louis, MO, USA) 
DNAse I Invitrogen Corp. (Paisley, UK) 
dNTP Mix MBI Fermentas (Vilnius, Lithouania) 
Dulbecco`s modified Eagle medium 
(DMEM) 
Invitrogen Corp. (Paisley, UK) 
Ethanol Merck (Darmstadt, Germany) 
Ethylenediaminotetracetic acid (EDTA) Merck (Darmstadt, Germany) 
Ethidium bromide Sigma (St. Louis, MO, USA) 
Fetal Calf Serum (FCS) Gibco (Karlsruhe, Germany) 
Fixer solution Kodak (Stuttgart, Germany) 
3H-Thymidine Amersham Biosciences (Uppsala, Sweden) 
Hexanucleotide Mix Roche (Mannheim, Germany) 
iE-DAP (γ-D-glutamyl-meso 
diaminopimelic) 
Invivogen (San Diego, California, USA) 
Isopropanol Sigma (St. Louis, MO, USA) 
L-Glutamine Biochrome AG (Berlin, Germany) 
Lipofectamine 2000 Invitrogen Corp. (Carlsbad, CA, USA) 
Luciferin Detection Reagent Promega Corp. (Madison, USA) 
Lumi-Light Western Blotting Substrate Roche (Mannheim, Germany) 
LY294002 (PI3 Kinase Inhibitor) Calbiochem (La Jolla, CA, USA) 
Marker Precision Plus Protein™Standards Bio-Rad (California, USA) 
1kb Plus DNA Ladder™ Invitrogen Corp. (Paisley, UK) 
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MDP (Muramyl dipeptide) Bachem AG (Bubendorf, Switzerland) 
Methanol Merck (Darmstadt, Germany) 
Milk powder (Frema Reform Instant 
Magermilchpulver) 
GRANOVITA GmbH (Heimertingen, 
Germany) 
ONPG solution Sigma (St. Louis, Mo, USA) 
Optimem medium Gibco Europe (Karlsruhe, Germany) 
Paraformaldehyde (PFA) Merck (Darmstadt, Germany) 
Partricine Biochrome AG (Berlin, Germany) 
Phosphate based buffer (PBS) Gibco Europe (Karlsruhe, Germany) 
PhosSTOP Phosphatase Inhibitor Cocktail 
Tablets 
Roche (Mannheim, Germany) 
Penicillin + Streptavidine mix Biochrom AG (Berlin, Germany) 
Phenol Roth (Karlsruhe, Germany) 
Polyacrylamide Invitrogen Corp. (Paisley, UK) 
Ponceau S Solution Sigma (St. Louis, Mo, USA) 
Protease Inhibitor Cocktail Sigma (St. Louis, Mo, USA) 
RNAse A Roche (Mannheim, Germany) 
RNAsin (RNAase inhibitor) Promega Corp. (Madison, WI, USA) 
Roti-Histokitt Roth (Karlsruhe, Germany) 
Roti®-Load1 Roth (Karlsruhe, Germany) 
Reverse transcriptase (SuperScript II TM) Invitrogen (Carlsbad, CA, USA) 
Running buffer (SDS) Anamed (Groß-Bieberau, Germany) 
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Sodium acetate dihydrate  Merck (Darmstadt, Germany) 
Sodium acetate trihydrate Merck (Darmstadt, Germany) 
Sodium chloride (NaCl)  Roth (Karlsruhe, Germany) 
Sodium citrate dihydrate Merck (Darmstadt, Germany) 
Sodium dihydrogen phosphate 
monohydrate (NaH2PO4-H2O) 
Merck (Darmstadt, Germany) 
Sodium hydrogen phosphate  
dihydrate (Na2HPO4-2H2O) 
Merck (Darmstadt, Germany) 
Sodium peroxyde (NaOH) Merck (Darmstadt, Germany) 
Streptavidine-horseradish-Peroxidase-
complex 
R&D Systems (Wiesbaden-Nordenstadt, 
Germany) 
Taq DNA polymerase MBI Fermentas 
Toluidine Blue O Sigma (St. Louis, Mo, USA) 
Transferrin Sigma (St. Louis, Mo, USA) 
Trichloroacetic acid Roth (Karlsruhe, Germany) 
Tris pure ICN Pharmaceuticals (Aurora, OH, USA) 
Triton X-100 Roth (Karlsruhe, Germany) 
TRIZOL Invitrogen (Carlsbad, CA, USA) 
Trypsin Sigma (St. Louis, Mo, USA) 
Tween 20 Sigma (St. Louis, Mo, USA) 
Ultima Gold Scintillation Solution Packard Bioscience (Gromingen,  
Netherlands) 
 
30 
 
3.1.3 Solutions 
Collagenase Mix 1000 U/ml  
Collagenase: 4 g/ 100 ml solution  
Trypsin inhibitor: 10 mg/ 100 ml solution  
Hyaluronidase: 100 mg/ 100 ml solution 
BSA: 400 mg/ 100 ml solution  
Dnase: 500 µl/ 100 ml solution  
HDB+ buffer Hepes: 5.95 g/l  
NaCl : 8 g/l  
KCl: 0.37 g/l  
Na2HPO4-H2O: 0.12 g/l  
Glucose: 1.982 g/l  
Partricine 25 µg/ml: 10 ml 
Penicillin/Streptomycin 105 U/l : 10 ml  
Adjust pH to 7.3 with NaOH  
Store at +4°C 
ONPG buffer 2x 1 M Na2HPO4  44 ml 
1 M NaH2PO4  16.13 ml 
H2O   270 ml 
MgCl2-6H2O  123 mg 
ONPG                               398 mg 
stirring 40 minutes 
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+ 2 ml B-Mercaptoethanol (14M) 
Stripping buffer to prepare 500 ml solution: 
50 ml 20% SDS 
25 ml 1 M Tris/HCl pH 7.4 
425 ml H2O 
+ add DTT 50 mM (final concentration) 
RIPA buffer 50 mM Tris HCl pH 8 
150 mM NaCl 
1% NP-40 
0.5% Sodium Deoxycholate 
0.1% SDS 
Running buffer 1x to prepare 1 l solution: 
anamed running buffer: 100 ml + 900 ml 
distilled water 
Paraformaldehyde (PFA) 4% paraformaldehyde: 4 g/100 ml  
Sodium phosphate buffer: 20 ml/100 ml  
Ampuwa water: 80 ml  
Add 1 M NaOH to pH 7.4  
Heat at 56°C to dissolve  
Filter and cool before usage  
Store at +4°C for maximum 2 days 
Transferbuffer 14.4 g Glycin  
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3.03 g Tris-Base 
0.5 g SDS 
200 ml Methanol 
completed with 800 ml H2O 
Tris borate EDTA buffer (TBE) 10x Boric acid (H3BO3): 61.83 g/l 
EDTA: 37.2 g/l 
Tris pure: 30.03 g/l 
pH: 8.0 
Tris buffer (TB) Tris pure: 12.114 g/l 
pH: 7.6 
Tris-based buffer (TBS)1x Tris pure: 2.42 g/l 
NaCl: 8 g/l 
pH: 7.6 
TBST  TBS + 0.1% Tween 20 
Tumor medium 
 
 
DMEM (Dulbecco´s Modified Eagle´s 
Medium)  
2 mM Essential Vitamins  
40 U/l Insulin  
20 ng/l Natrium Selenate  
5 mg/l Transferrin  
30 pM Triiodothyronine (T3) 
10% Fetal Calf Serum 
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2 mmol/l L-glutamine  
2.5 ng/l Partricine 
105 U/ml Penicillin-Streptomycin 
 
3.1.4 Antibodies 
Primary antibodies used for Western immunoblotting            
Target protein Species; dilution Company 
BAX rabbit; 1:1000 Cell Signaling Technology 
BCL-2 rabbit; 1:1000 Cell Signaling Technology 
CDK2 rabbit; 1:1000 Cell Signaling Technology 
CDK4 mouse; 1:1000 Cell Signaling Technology 
Cyclin D1 mouse; 1:1000 Cell Signaling Technology 
Cyclin D3 mouse; 1:1000 Cell Signaling Technology 
Cyclin E mouse; 1:1000 Cell Signaling Technology 
p21 mouse; 1:500 Cell Signaling Technology 
p-AKT Ser473 rabbit; 1:2000 Cell Signaling Technology 
p-AKT Thr308 rabbit; 1:2000 Cell Signaling Technology 
p-ERK1/2 rabbit; 1:1000 Cell Signaling Technology 
p-FOXO rabbit; 1:1000 Cell Signaling Technology 
p-GSK-3β rabbit; 1:1000 Cell Signaling Technology 
p-JNK mouse; 1:1000 Santa Cruz Biotechnology 
p-mTOR Ser2448 rabbit; 1:1000 Cell Signaling Technology 
34 
 
p-NF-κB rabbit; 1:1000 Santa Cruz Biotechnology 
p-P38 mouse; 1:1000 Santa Cruz Biotechnology 
p-p70S6K Thr389 rabbit; 1:1000 Cell Signaling Technology 
p-PTEN rabbit; 1:1000 Cell Signaling Technology 
p-Raptor Ser792 rabbit; 1:1000 Cell Signaling Technology 
p-Rb Ser780 rabbit; 1:500 Cell Signaling Technology 
p-Rb Ser795 rabbit; 1:500 Cell Signaling Technology 
t-AKT rabbit; 1:1000 Cell Signaling Technology 
t-ERK 1/2 rabbit; 1:1000 Cell Signaling Technology 
XIAP rabbit; 1:1000 Cell Signaling Technology 
β-actin (beta-actin) mouse; 1:20.000 Chemicon 
 
Secondary antibodies used for Western immunoblotting 
Name Dilution Company 
anti-rabbit-HRP 1:1000 Amersham Biosciences 
(Freiburg, Germany) 
anti-mouse-HRP 1:1000 Amersham Biosciences 
(Freiburg, Germany) 
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Antibodies used for Immunohistochemistry 
Antigens Primary antibodies Secondary biotinylated 
antibodies 
NOD1 (E-14) Goat anti-human  
(Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) 
Horse anti-goat  
(Vector Laboratories Inc., 
Burlingame, CA) 
NOD2 (P-18) Goat anti-human  
(Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) 
Horse anti-goat  
(Vector Laboratories Inc., 
Burlingame, CA) 
 
3.2 Human tissues 
 This study was performed after approval of the Max Planck Institute`s ethics committee 
(ethics appliciation number: 141-07) and informed consent was received from each 
patient or their relatives. 4 normal human pituitaries and 33 pituitary adenomas were 
included in the study. The pituitary tumors were obtained from the neurosurgical clinic 
(LMU Klinikum Großhadern). The normal pituitary glands (NP) were obtained from the 
autopsy of the Institute of Forensic Medicine less than 20 hours post mortem. The 
studied pituitary tumors were obtained from transsphenoidal surgery of 33 patients: 15 
males and 18 females, classified according to clinical presentation into 7 
somatotropinomas (ACRO), 6 corticotropinomas (CUSH), 8 non functioning pituitary 
adenomas (NFPA), 8 prolactinomas (PROL) and 4 thyreotropinomas (TSH) (Table 1). All 
the tumors were benign and tumor grade was determined according to a modified 
Hardy´s classification [121]. Tissue fragments of normal pituitaries and pituitary 
adenomas were placed in DMEM medium and transferred to our laboratory on ice 
within 36 hours. After washing, one aliquot was shock-frozen on dry ice and stored at -
80°C until use. 
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Table 1: studied pituitary tumors. 
CUSH = corticotropinomas; 
NFPA = non functioning pituitary adenomas; 
ACRO = somatotropinomas; 
TSH = thyreotropinomas; 
PROL = prolactinomas; 
NP = normal pituitaries 
 
 
 
 
 
3.3 Cell culture 
3.3.1 Primary rat pituitary cell culture and human pituitary cell culture 
The pituitary primary cell culture was obtained from adult male Sprague-Dawley rats 
(180-250 g). They were kept for 5 days in our animal house under standard conditions: 
12 hours light/dark rhythm, temperature 21°C, water and standard food. After CO2 
narcosis and decapitation, the pituitary glands were quickly removed and stored in 
HDB+ buffer. Pieces of human pituitary adenomas, destined for cell culture, were 
handled in the same way as rat pituitary cell culture cells. Sliced fragments were 
  age  (m/f) Type   age  (m/f) type 
1 63 f CUSH 22 40 F TSH 
2 70 f CUSH 23 58 F TSH 
3 39 m Nelson 24 40 F TSH 
4 31 f CUSH 25 55 M TSH 
5 66 f CUSH 26 43 M PROL 
6 48 f CUSH 27 34 M PROL 
7 68 m NFPA 28 66 M PROL 
8 69 f NFPA 29 34 F PROL 
9 48 f NFPA 30 37 M PROL 
10 41 m NFPA 31 46 M PROL 
11 78 f NFPA 32 79 M PROL 
12 38 f NFPA 33 28 M PROL 
13 62 m NFPA 34 - - NP 
14 74 f NFPA 35 - - NP 
15 36 m ACRO 36 - - NP 
16 82 f ACRO 37 - - NP 
17 56 m ACRO 
    18 28 f ACRO 
    19 42 f ACRO 
    20 38 m ACRO 
    21 84 f ACRO 
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enzymatically dispersed in the Collagenase mix buffer at 37°C for approximately 45 
minutes. Dispersed cells were centrifuged and resuspended in tumor medium. Cell 
viability was determined by fluorescence microscopy after staining with acridin orange 
and ethidium bromide. Acridin orange enters the membranes of normal cells, yielding 
green fluorescence in viable cells. Ethidium bromide does not pass the healthy cell 
membrane and enters only in dead cells with damaged membranes, yielding a red 
fluorescence. Cell viability of pituitary cells was determined as the percentage of green 
cells in the total number of cells (counted in a Neubauer chamber) and was over 95%. 
Cells were distributed in 48-well plates (1 x 105 cells per well) and incubated at 37°C 
under 5% CO2. The stimulation experiments were performed 48 hours after preparation 
[122].  
3.3.2 Immortalized corticotroph cell line AtT20 
The expression and functional studies on cell growth and signaling of NOD1 and NOD2 
proteins were performed in AtT20 cells. This immortalized corticotroph cell line was 
obtained from the American Type Culture Collection (Rockville, MD, USA). The AtT20 
cell line originates from a murine ACTH-secreting pituitary tumor [2]. The medium used 
for their culture was DMEM supplemented with 10% FCS (fetal calf serum), 1% L-
Glutamin, 1% Patricine and 1% Penicillin/Streptomycin. They were kept in 75 cm2 cell 
culture bottles in incubators at 37°C in the presence of 5% CO2. When confluent, the cells 
were trypsinized, centrifuged at 1200g for 4 minutes and re-dispersed in fresh medium. 
They were numbered and replaced in new cell culture bottles, or plated in different well-
plates according to the planned experiments. For transfections, the cells were plated in 
24-well plates at a density of 2 x 105 cells per well and all experiments were carried out 
in triplicate. For hormone measurements and cell proliferation experiments, the cells 
were plated in 96-well plates using 8 x 103 cells per well and in 48-well plates with 1 x 
105 cells per well, and ultimately carried out in quadruplicate. The experiments were 
performed 24 hours after cell seeding. 
3.3.3 Cell proliferation assay WST-1 and [3H]-thymidine incorporation 
24 hours after seeding, the cells were first serum deprived by overnight incubation with 
serum-free medium before performing the experiment. This step synchronized all the 
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cells to the cell cycle phase G0. The stimulation with 30 μg/ml of iE-DAP and 30 μg/ml of 
MDP was stopped after 48 hours. 
WST-1 is one of the assays available for analyzing the number of viable cells by 
measuring the cleavage of tetrazolium salts added to the culture medium. The WST-1 
measures the metabolic activity based on the reduction of WST-1 by viable cells. The 
WST-1 (tetrazolium salt) added to the cells is converted by the mitochondrial 
dehydrogenase into a dye (formazan), that can be quantified by a multiwall scanning 
spectrophotometer (ELISA plate reader). The stimulation time was stopped by adding 
10 μl WST-1 reagent to each well containing 100 μl of cells in medium. After 15 to 30 
minutes, the results were measured in the ELISA reader at 450 nm. 
Proliferation was also measured by using the [3H]-thymidine incorporation method. The 
radioactivity, incorporated in the DNA of the stimulated cells during S phase of the cell 
cycle, is an indicator of the cells expansion rate. During the last three hours of 
incubation, 0.5 µCi/ml [3H]thymidine was added, then medium was removed and after 
one wash in cold PBS, cells were precipitated with ice-cold 10% trichloroacetic acid (1 
hour, 4°C) and washed with cold PBS. Then, DNA was hydrolyzed overnight with 0.5 M 
NaOH/0.1% Triton X-100. The scintillation liquid cocktail, Ultima Gold, was added and 
the samples were measured in a liquid scintillation counter.  
3.4 Molecular Biological Methods 
3.4.1 RNA Extraction 
RNA was isolated from normal human pituitaries and from human pituitary adenomas 
using the guanidium isothiocyanate protocol. The tissue piece was first homogenized in 
80 µl of solution D containing β−mercaptoethanol, using the Ultra-TURRAX T8 (IKA 
Labortechnic) tissue homogenizer. Guanidium isothiocyanate and β−mercaptoethanol 
inhibit the RNAase action activated by cell disruption, preventing in this way RNA 
degradation. 80 µl of sodium acetate 2 M pH 4.0 was added afterwards, followed by 800 
µl of saturated phenol and 160 µl of a chloroform-isoamyl alcohol (49:1) solution. After 
15 minutes incubation on ice the samples were centrifuged at 13000 rpm for 20 minutes 
at 4°C; this step led to the formation of two phases, the upper one containing RNA and 
the lower one containing DNA and proteins. The upper phase was then transferred to a 
new tube together with the same volume of ice-cold isopropanol. Incubation of the 
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sample at –20°C at least for 2 hours was necessary for RNA precipitation. After 
centrifugation of the sample at 13000 rpm for 10 minutes at 4°C, the supernatant was 
discarded and the pellet was washed with 70% ice-cold ethanol. After 10 minutes 
centrifugation at 13000 rpm, the supernatant was again discarded and the pellet was 
left to dry at room temperature and then dissolved in an appropriate amount of DEPC 
treated water.  
RNA extraction from AtT20 cells was performed as follows: Cells were seeded in 6-well 
plates, starved overnight and stimulated with 30 μg/ml of iE-DAP and 30 μg/ml of MDP 
for 24 hours, after which the medium was removed from the wells. 1 ml of TRIzol 
reagent was added to each well and the cells were passed several times through a 
pipette to obtain homogenization. During this step, the TRIzol Reagent maintains the 
integrity of RNA while disrupting cells and dissolving cell components. The 
homogenized samples were transferred into GEL-tubes (Phase Lock Gel Heavy Tubes, 5 
Prime GmbH) and left at room temperature for 5 minutes to allow the complete 
dissociation of nucleoprotein complexes. Following incubation, 0.2 ml of chloroform was 
added to the tubes. They were shaken by hand and left again at room temperature for 
incubation for 2-3 minutes. Afterwards, the tubes were centrifuged at 12000g for 15 
minutes at 4°C. Addition of chloroform and centrifugation separates the mixture into a 
lower phenol-chloroform phase (contains proteins), an interphase (contains DNA) and a 
colorless upper aqueous phase. The RNA remains exclusively in the aqueous phase. This 
RNA containing aqueous phase was transferred to fresh tubes and the RNA was 
precipitated by adding 0.5 ml of isopropyl alcohol to the tubes. Incubation at room 
temperature for 10 minutes and another centrifugation step followed. The RNA 
precipitate, often invisible before centrifugation, forms a gel-like pellet on the side and 
bottom of the tube. The supernatant was removed and the RNA pellet washed with 1 ml 
75% ethanol. The samples were mixed by vortexing, followed by a final centrifugation 
step at 7500g for 5 minutes at 4°C. The final step of the procedure was to briefly dry the 
RNA pellet at 60°C. It is important not to let the RNA pellet dry completely, as this will 
greatly decrease its solubility. The RNA was dissolved in DEPC water by passing a few 
times through a pipette tip and incubating for 10 minutes at 60°C.  
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The samples` absorbance was measured with a photometer and RNA concentration 
calculated according to the following formula:  
    
cRNA =
A260 ∗ 40 ∗ 60
1000
 [μg/ml] 
 
A260 is the sample absorbance at 260 nm, 40 is the concentration in µg/µl of RNA giving 
A260 value equal to one and 60 is the dilution factor used to measure the sample 
concentration (1 µl RNA+ 59 µl DEPC water). Partially dissolved RNA samples have an 
A260/A280 ratio < 1.6. The lack of DNA contamination was assessed by performing a 
PCR reaction for a housekeeping gene like HPRT or β−actin, using the RNA as a sample: 
if no DNA contamination is present, no band is visible after loading the PCR product on 
an ethidium bromide gel (as described below). 
3.4.2 RT-PCR (Reverse Transcriptase- Polymerase Chain Reaction) 
Reverse Transcription is a process in which single-stranded mRNA is reverse 
transcribed into complementary DNA (cDNA) by using total cellular RNA. The resulting 
cDNA can be used in PCR reaction. Reverse transcription of RNA samples was performed 
by incubating the following substances for one hour at 45°C: 1 µg RNA with 1 µl of dNTP 
mix 2 mM, 2 µl of 62.5 U/ml random primers (Hexanucleotide mix), 2 µl of dithiothreitol 
(DTT) 10 mM and 200 U reverse transcriptase (SuperScript II), all diluted in 4 µl of 1x 
first strand buffer and DEPC-water to get a final volume of 20 µl. Reaction was stopped 
by boiling the samples at 95°C for 5 minutes, followed by cooling down on ice for 5 
minutes.  
PCR (Polymerase chain reaction) is a rapid method of copying and amplifying specific 
DNA sequences and is widely used as a preparative and analytical technique. The 
method relies on the use of short oligonucleotide primers complementary to the 
sequences at the ends of the DNA to be amplified, and involves repetitive cycles of 
melting, annealing and synthesis of DNA. One µl of cDNA samples obtained was used for 
PCR reaction and incubated with 1.5 µl PCR buffer 10x, 0.9 µl MgCl2 25 mM, 1.5 µl dNTP 
mix 2mM, 0.5 µl amplification primer sense 10 pmol/µl, 0.5 µl amplification primer anti-
sense 10 pmol/µl, 0.15 µl Thermus aquaticus (Taq) DNA polymerase and 8.95 µl 
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autoclaved distilled water. The PCR reaction consisted of 35 cycles, each containing the 
following steps: denaturation at 94° C for 1 minute, annealing at 55°C- 65°C according to 
the employed primers specific annealing temperature (Table 2) for 1 minute and finally 
elongation of the PCR fragment at 72° C for 1 minute.  
 
Table 2: 1st column: name of the gene; 2nd column: sense and antisense primer sequences; 3rd column 
annealing temperature; 4th column: expected fragment size   
 
 
The amplified fragments were electrophoresed in 1.5% agarose gel, in 1 x TBE buffer for 
15-20 minutes at 80 V and then visualized by ethidium bromide under UV light. The 1 kb 
Plus DNA Ladder marker was used to determine the fragment size. In table 2, the 
primers used are listed together with the corresponding sequence, annealing 
temperature and expected length of the amplified fragment. Each sequence was checked 
with the NCBI BLAST program in order to exclude eventual annealing with other genes 
different from the ones studied. All primers were synthesized by MWG Biotech, 
reconstituted with sterile distilled water to a concentration of 100 µM and stored at -20 
° C.  
 
 
Primer Sequence [5`→ 3`] Temperature 
[ºC] 
Length [bp] 
NOD1 mouse GTC CTC AAC GAG CAT GGC GAG ACT sense 
AGC TCA TCC AGG CCG TCA A antisense 
60 300 
NOD2 mouse GCT GCC AAT CTT CAC GTC GTC sense 
TAA GTA CTG AGG AAG CGA GAC TGA antisense 
60 180 
NOD1 human GTA AAG GTG CTA AGC GAA GA sense 
TCT GAT TCT GGA TAA GCC AT antisense 
55 470 
NOD2 human AAC CAC TCT CTG TGC GGA CT sense 
CCT GTT CAG AGA AGC CCT TG antisense 
60 350 
p27 mouse GAG GGC AGA TAC GAA TGG CAG sense 
CTG GAC ACT GCT CCG CTA ACC antisense 
60 238 
HPRT mouse AAC TCT CGA AGT GTT GGA TAC AGG sense 
CTT GCG CTC ATC TTA GGC TTT G antisense 
55 168 
β-actin ACG GGG TCA CCC ACA CTG TGC sense 
CTA GAA GCA TTT GCG GTG GAC GAT G 
antisense 
60 660 
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3.5 Luciferase reporter gene assay 
3.5.1 Plasmids 
Plasmids are circular DNA molecules used for studying the control of gene expression 
and investigating the regulatory elements and cell signaling. Plasmids used in molecular 
biology contain an antibiotic resistance gene, which helps to select only the host bacteria 
resistant to a certain antibiotic during the transformation step. There are expression and 
reporter plasmids. An expression plasmid is used to introduce a specific gene into a 
target cell. Once the expression vector is inside the cell, the protein that is encoded by 
the gene is produced by the cellular transcription and translation machinery. The 
expression plasmids used in this study are: NOD2 expression plasmid pcDNA3 HA-NOD2 
and control plasmid pcDNA3 HA (provided by Dr. Gabriel Nunez, University of Michigan 
Medical School, Ann Arbor, MI, USA). As an expression plasmid for NOD1 was not 
available, the experiments of this study related to overexpression were performed only 
with the NOD2 expression plasmid. Reporter plasmids contain a fusion gene, in which 
the promoter of an endogenous gene is coupled to the reporter gene, whose product is 
easier to detect. If the endogenous gene promoter is “turned off”, neither the 
endogenous gene nor the reporter gene is transcribed. Likewise, if the promoter for the 
endogenous gene is activated, then the reporter gene is also transcribed. All the reporter 
plasmids in this study contain the reporter luciferase. Upon addition of its substrate 
luciferin, the release of light is catalyzed by the firefly luciferase enzyme. The emission 
peaking at 562 nm is easily measured in a luminometer and correlates with the 
transcription of the gene promoter coupled to luciferase in a certain plasmid. The 
reporter plasmids used in this work are: NF-κB-Luc (provided by Dr. Bell, Mayo Clinic, 
Rochester, MN, USA), POMC-Luc (Dr. M. Low, Oregon Health and Science University, 
Portland, USA), p53-Luc (Mercury pathway profiling system, Clontech Laboratories, Inc., 
Palo Alto, CA, USA), NurRE-Luc (Dr. J. Drouin, Montreal, QC, Canada) and AP-1-Luc 
(Stratagene, La Jolla, California, USA). 
3.5.2 RNA interference 
Regulation of eukaryotic gene expression occurs at different stages of protein 
biosynthesis: at the transcriptional, RNA processing and translational levels and at the 
level of protein maturation/degradation. The post-transcriptional level has recently 
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attracted much attention because of the discovery of the phenomenon called RNA 
interference (RNAi) [123]. RNAi is initiated by the enzyme Dicer (an endoribonuclease 
RNase III), which cleaves long double-stranded RNA (dsRNA) molecules into short 
fragments of 21–25 base pairs with a few unpaired overhang bases on each end. These 
short double-stranded fragments are called small interfering RNAs (siRNAs). The 
siRNAs are then separated into single strands and integrated into an active RISC (RNA 
induced-silencing complex) complex. After integration into RISC, the siRNAs base-pair to 
their target mRNA and induce cleavage of the mRNA, thereby preventing it from being 
used as a translation template. The whole process of interference is shown in figure 11. 
 
 
 
 
 
 
 
 
 
Fig. 
11: RNA interference process 
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SiRNA for targeting endogenous NOD1 and NOD2, as well as a non-targeting siRNA, used 
as a control (siRNA control) sequence, were obtained from Santa Cruz Biotechnology. 
AtT20 cells were transfected using 13 nM siRNA for 24 hours. The transfection 
experiments were performed as described in the following section. 
3.5.2 Transfections 
Lipofection was successfully used for transfections. The principle of lipofection is based 
on the formation of a DNA-liposome complex between the positively charged 
lipofectamine and the negatively charged DNA, which subsequently leads to the fusion 
with a cell membrane and the uptake of the DNA into the cell.  
The day before the experiment, AtT20 cells were seeded in 24-well plates at a density of 
2 x 105 cells per well using 500 μl of normal DMEM medium containing 10% FCS with all 
nutrients. To prepare the transfection mix, Opti-MEM® Medium was used, as this 
reduced serum media is ideal for cationic lipid based transfections. For each well a 
mixture was prepared containing 0.8 μg DNA (in total), 2 μl of Lipofectamine 2000, and 
since NOD expression is restricted to the cytoplasm, the stimulus for NOD1 and NOD2 
were also included into the mix in the desired concentration. The RSV-β-gal construct 
was also included to the mix to verify later in parallel the efficiency of the transfection 
(described below). The mix was left for incubation under the laminar flow for 20 
minutes. Meanwhile, 100 μl of medium from each well was removed from the 
transfection plate. Following the incubation time of the Lipofectamine 2000 mixture, 
100 μl of the mix was added to each well. According to the experiment performed, the 
transfection and stimulation time varied. After the transfection and stimulation time, the 
supernatant was removed and the cells were washed with PBS. 100 μl of lysis buffer 
(diluted 1:5 in water) was added to the wells and stored on the shaker at room 
temperature for 15 minutes. Afterwards, the plate was stored at -80° C just until the 
cells got frozen. After thawing, the cells were transferred to Eppendorf tubes and 
centrifuged for one minute. 20 μl of the supernatant were plated in a non-transparent 
96-well plate, which was placed in the TriStar machine that automatically added 50 μl of 
luciferin to each well and measured the luciferase activity.  
The transfection efficiency was determined in parallel by performing the β-galactosidase 
assay. 20 μl of the supernatant, 30 μl of distilled water and 50 μl of ONPG buffer were 
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placed on an ELISA-reader plate. The light protected plate was stored in the incubator 
for 10-60 minutes until the solution began to turn yellow and the absorption could be 
measured. Results are shown as percentage with respect to control plasmids or basals, 
and are ratios of luciferase to β-gal activity, in order to normalize the results according 
to the transfection efficiency in each well. All experiments were carried out in triplicate 
and repeated three times independently.  
3.6 Biochemical Methods 
3.6.1 Protein extraction 
To perform SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
immunoblotting, AtT20 cells were seeded on 6-well plates with a density of 1 x 106 per 
well. The next day, they were starved for 24 hours and afterwards stimulated with 30 
μg/ml iE-DAP and 30 μg/ml MDP for the desired time. After the stimulation time 
elapsed, the supernatant was removed from the plate, the cells were washed with PBS, 
scraped with 500 μl PBS and transferred to Eppendorf tubes. Following, they were 
centrifuged at 1400 rpm for 10 minutes at 4 °C. The supernatant was discarded and the 
protein extracted through breaking the cell membranes by adding 150 μl of RIPA lysis 
buffer, 1:10 PhosSTOP Phosphatase Inhibitor Cocktail and 1:100 protease inhibitor 
cocktail, all diluted in distilled water. The whole procedure was performed on ice. The 
samples were sonicated before they were used for SDS-PAGE or stored at -20°C.  
3.6.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
After the final sonication step of the protein extraction the samples were centrifuged, 
after which the supernatant contained the proteins. 15 μl of proteins were mixed with 5 
μl of Roti®-Load1 loading buffer and boiled at 95°C for 5 minutes. Electrophoresis was 
carried out using a pre-cast Tris-Glycine 10% gel in an Invitrogen XCell SureLock™ Mini-
Cell electrophoresis apparatus at a constant voltage of 130V for 1-1.5 hours. This 
separates the proteins by size and in order to monitor progress of protein 
electrophoresis and molecular weight of blotted proteins, the Marker Precision Plus 
Protein™Standards was used. 
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3.6.3 Western immunoblotting 
The Western Blot is a technique for detection of proteins in different samples such as 
tissues or cell extracts, serum, liquor or cell culture supernatants. After separation of the 
proteins by electrophoresis, they are transferred to different types of membranes and 
detected by various methods, among them by immunological methods. The latter allows 
the measurement of the relative amount of a specific protein present in the samples. 
This is possible by using a primary specific antibody directed against the studied 
protein, which is detected by a secondary antibody (horseradish peroxidase-conjugated) 
and visualized on a nitrocellulose membrane, after incubation with a substrate 
developing a luminescent product. In this study PVDF membranes were used because of 
their higher binding capacity compared to nitrocellulose membranes. Before usage, the 
PVDF (Polyvinylidene fluoride) membranes were first pretreated by soaking them for 15 
seconds in methanol, then 2 minutes in distilled water and at least 5 minutes in transfer 
buffer. The “semi-dry”- method, by using the Invitrogen Novex® Semi-Dry Blotter, is a 
system that allows efficient and rapid electrophoretic transfer of proteins. The blotting 
is performed with plate electrodes in a horizontal configuration, sandwiching gel and 
membrane between sheets of transfer buffer soaked filter paper that functions as the ion 
reservoir. During electrophoretic transfer at 150 mA for one hour, negatively charged 
molecules migrate out of the gel, move towards the positive electrode, and encounter 
the membrane, where they bind. Afterwards, the membrane was soaked again for 15 
seconds in methanol, 2 minutes in distilled water and stored on a filter paper to dry. 
Next, the Ponceau S solution dye was used to make a rapid reversible stain of the 
membrane to verify that the amount of protein was equal in every sample. The staining 
was easily removed by water washing, followed by a blocking step for one hour at room 
temperature in 5% milk powder, diluted in 1x TBST. Afterwards, the primary antibody 
was prepared in the desired dilution in 5% BSA and incubated overnight at 4°C. After 
three washes with TBST the following morning, the membrane was incubated with the 
secondary antibody diluted in 5% milk powder for one hour at room temperature. The 
secondary antibody is conjugated to Horseradish Peroxidase, an enzyme which allows 
visualization of the reaction. The detection was carried out by using ECL Western 
Blotting Detection System. The acridan-based substrate used in this system releases a 
high level sustained output of light, which can be detected by an x-ray film exposed to 
the membrane in an autoradiography cassette, to detect the light given off by the 
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enzyme reaction. The film was removed and developed to visualize the 
immunoreactivity bands. The bands were present wherever there was a protein-
primary antibody-secondary antibody-enzyme complex, or in other words, wherever the 
protein under investigation was. In order to confirm the equal protein amount in every 
sample, the procedure was repeated using antibodies detecting the total protein levels, 
or the anti-β-actin antibody, an antibody against a highly conserved protein found in all 
eukaryotic cells. 
3.6.4 Hormone measurement by RIA (Radioimmunoassay) 
RIA (Radioimmunoassay) is a highly sensitive and quantitative technique used for the 
measurement of substances such as enzymes, proteins and hormones that exist in very 
low concentrations. In this study, the RIA was used to measure the concentration of rat 
and mouse ACTH levels secreted in the medium by primary rat pituitary cultures and 
AtT20 cells. RIA uses radiolabeled antigens (Ag) to detect Ag:Ab (antibody) reactions. 
The procedure follows the basic principle of radioimmunoassay, where there is 
competition between a radioactive and a non-radioactive antigen for a fixed number of 
specific antibody binding sites. The antigens are labeled with the I125 (iodine-125) 
isotope, and the presence of Ag:Ab reactions is detected using a gamma counter.  
The first step for starting the RIA is developing an antibody that is highly specific for the 
hormone being measured. An N-terminal specific antibody against rat ACTH was raised 
in rabbits using an antigen produced by the two-step carbodiimid method [124]. 
Standards were purchased from Bachem. A small quantity of the antibody was mixed 
with a certain quantity of the sample (cell culture supernatant) containing the hormone 
to be measured. At the same time, a certain amount of tracer (standard antigen labeled 
with the radioactive isotope I125) was added to the mixture. The samples were incubated 
one hour at 37°C, allowing time for the hormone (Ag) to bind to the antibody. The 
mixture was prepared in such quantities that there were not enough antibodies to bind 
with both the labeled hormone and with the hormone to be measured, so the natural 
hormone and the labeled hormone competed for binding sites. The quantity of each 
hormone bound was proportional to their concentration, and the amount of labeled 
hormone (tracer) bound to the specific antibody was inversely proportional to the 
concentration of the natural hormone. After binding had reached the equilibrium, the 
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quantity of radioactive hormone bound to the antibody was measured in a gamma 
counter. As explained above, the amount of radioactivity present in the test was 
inversely proportional to the amount of hormone in the sample. Quantification of the 
unknown free hormone in the sample was achieved by comparing their activity with a 
standard curve prepared by using increasing amounts of known concentrations of the 
hormone. To study the effect of NOD receptor ligands on ACTH production, the primary 
rat pituitary cell culture and the AtT20 cells were serum deprived overnight, stimulated 
for 24 and 48 hours with 30 μg/ml of iE-DAP and 30 μg/ml of MDP in medium 
containing 2%  FCS, and afterwards the supernatants were collected for ACTH analysis 
by RIA. 
3.6.5 Single Immunohistochemistry (IHC) 
The technique of IHC is useful to visualize the localization and expression intensity of a 
specific protein within a cell or tissue. The basic principle of this method (Fig. 12) is the 
ability of antibodies to specifical recognize particular subsequences of a protein, called 
epitopes. The technique involves three steps. In the first step an unlabeled primary 
antibody, specific for the protein of interest, binds to its target in fixed cells or tissue 
slices. In the second step a biotinylated secondary antibody, raised against the 
antibodies of the animal in which the primary antibody was produced, binds to the 
primary antibody. In the third step a complex of avidin-biotin peroxidase is created. 
Biotin, a low molecular weight vitamin, can be conjugated to a variety of biological 
molecules such as antibodies. Avidin, a large glycoprotein, is labeled with peroxidase 
enzyme and has a very high affinity for biotin. The peroxidase produces a brown 
precipitate actin on the chromogen diaminobenzidine (DAB) and therefore makes the 
reaction visible at microscope.  
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Fig. 12: The principle of IHC. The antigen of interest is recognized by a specific primary antibody, which is 
in turn recognized by a biotinylated secondary antibody. The biotin is bound by avidin, conjugated with 
peroxidase, which is using respectively DAB as substrate and catalyzes a chromogenic reaction yielding a 
brown coloured product. 
AtT20 cells were seeded on slides and cultured for two days before they were fixed in 
4% paraformaldehyde (PFA), freshly prepared in PBS, and stored in 96% ethanol at 4° C 
until use. After a wash in 1 x TBS for 5 minutes, slides were first blocked for 30 minutes 
in serum (diluted 1:10 in 1 x TBS buffer pH 7.6) of the same animal in which the specific 
biotinylated secondary antibody was raised. Afterwards, the primary antibody was 
applied and the slides were left overnight at 4°C. The next day, after three washes in TBS 
buffer, the biotinylated secondary antibody was added at room temperature for 30 
minutes. After three further washes in TBS buffer, the slides were incubated with the 
avidin-biotin-peroxidase complex (ABC-complex) at room temperature. The ABC 
complex was prepared in Tris buffer at least 30 minutes in advance to allow the complex 
formation. The development was performed using freshly prepared 1 mg/ml DAB with 
0.01% hydrogen peroxide. DAB incubation time was different for each antibody and was 
decided by checking the brownish precipitate. Since DAB is light-sensitive, these final 
steps were performed in darkness. After three more washes, the slides were finally 
counterstained for 15 minutes in toluidine blue, which stains nuclei in light blue. Excess 
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of color was removed with two washes in distilled water and one final wash in 70% 
ethanol supplemented with acetic acid. Next, two dehydration steps in 96% ethanol and 
100% ethanol was followed before the slides were fixed in Roti-Histol and coverslipped 
using Roti-Histokitt. 
3.7 Statistics 
Hormone secretion assays were performed in quadruplicate wells, cell proliferation and 
transfection experiments were all performed in triplicate wells and results are 
expressed as mean ± standard error. For statistical analyses of stimulation experiments, 
the mean values were compared by one-way ANOVA. P values smaller than 0.05 were 
considered significant and marked with asterisks. For Western Blot bands and RT-PCR 
bands analysis, the software ImageJ 1.42 was used. After calibration, the software is able 
to convert the intensity of bands into numeric values, which then could be shown as a 
bar diagram. 
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4. Results 
4.1 Expression of NOD1 and NOD2 in the pituitary gland 
4.1.1 NOD proteins in the pituitary tumoral cell line AtT20 
In my diploma thesis, I previously examined the expression of NOD1 and NOD2 in the 
pituitary tumor cell line AtT20. I found the expression of these two intracellular 
receptors by RT-PCR and immunohistochemistry.  
4.1.2 NOD expression in normal human pituitaries and human pituitary adenomas 
 
Recently, NOD1 and NOD2 were shown to be implicated in tumorigenesis in various 
types of cancer [76, 78]. Since it was already demonstrated that immune receptor 
activation modulates pituitary tumor progression [79], the expression of NOD1 and 
NOD2 was also studied in the pituitary gland and in human pituitary adenomas. In four 
normal pituitary samples the expression of these two receptors could be detected by RT-
PCR (Fig. 13 a) and IHC (Fig. 13 b).  
 
 
 
 
 
 
 
 
Fig. 13 a + b: Detection of NOD1 and NOD2 in the human pituitary gland. 
a) mRNA expression levels of NOD molecules in human pituitaries (NP: normal pituitary). 
b) Arrows indicates NOD1 and NOD2 positive cells (brownish) in human pituitary 
a 
b 
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Next the importance of the expression in pituitary adenomas was examined and 
assessed. A detailed description of the human pituitary adenomas used is given in table 
1 (page 36). Interestingly, about half of the studied human pituitary adenomas had 
higher levels of expression when compared to the normal pituitary gland (Fig. 14). 
Somatotropinomas and corticotropinomas showed the highest and non functioning 
pituitary adenomas the lowest mRNA levels. The mRNA levels obtained were compared 
with the expression of the β-actin housekeeping gene. The normalized results could 
finally be presented as a bar chart. 
 
 
 
Fig. 14: Bar chart of human NOD1 and NOD2 mRNA expression values. The optical density was 
calculated by ImageJ based on the intensity of the RT-PCR bands. Abbrevations: NP (normal 
pituitary), Acro (somatotropinomas), PRL (prolactinomas), Cush (corticotropinomas), TSH 
(thyreotropinomas), NFPA (non functioning pituitary adenomas) 
All together the results indicate that NOD immune receptors are expressed in tumoral 
pituitary AtT20 cells as well as in normal pituitaries and human pituitary adenomas. 
This outcome suggests that these receptors are functional in the pituitary gland, and the 
elevated mRNA expression levels in a proportion of pituitary adenomas indicate a 
possible importance of these receptors in tumorigenesis. 
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4.2 NOD receptor activation and its impact on POMC activity and ACTH secretion 
As dysregulation of normal feedback processes seems to occur in adrenocorticotropic 
(ACTH)-secreting tumors, the physiological relevance of NOD expression in terms of 
hormone production was evaluated. In addition to ACTH secreting AtT20 cells, cells of 
normal rat pituitaries were also included in this set of experiments. 
4.2.1 NOD ligands downregulate POMC activation and ACTH secretion in AtT20 
cells 
POMC (Proopiomelanocortin) is synthesized by corticotrope cells of the anterior 
pituitary gland. It undergoes post-translational processing, which is essential for the 
production of bioactive peptides like ACTH. As shown by transfection of AtT20 cells with 
the POMC-Luc plasmid, treatment with 30 μg/ml of iE-DAP and MDP inhibited POMC 
promoter activity (Fig. 15).  
 
 
Fig. 15: NOD ligands inhibit POMC luciferase 
activity in AtT20 cells. AtT20 cells were 
transfected with POMC-LUC plasmid and 
stimulated with 30 μg/ml of iE-DAP and MDP. 
After 24 hours, luciferase activity was 
measured. Values are presented in percentage 
of control and as the mean ± SE (*** P < 0.001). 
 
 
 
By overexpressing NOD2 the inhibitory effect of NOD receptor activation on the POMC 
promotor could be repeated (Fig. 16). 
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Fig. 16: Decreased POMC luciferase activity in NOD2 overexpressed AtT20 cells. AtT20 cells were 
transfected with control plasmid or NOD2 expression vector along with POMC-LUC with or without 30 
μg/ml of MDP. 24 hours post-transfection, luciferase activity was measured. Values are presented in 
percentage of control and as the mean ± SE (* P < 0.05 and *** P < 0.001). 
 
POMC transcription depends on expression of Nur elements, which upon activation bind 
to the target DNA element on the POMC promoter [125]. The addition of NOD2 
overexpression plasmid resulted in a strong inhibition of NurRE luciferase activity (Fig. 
17).  
 
Fig. 17: Overexpression of NOD2 inhibited NurRE 
luciferase activity in AtT20 cells. AtT20 cells were 
transfected with control plasmids or NOD2 expression 
vector along with NurRE-Luc plasmid. 24 hours post-
transfection, luciferase activity was measured. Values 
are presented in percentage of control and as the mean 
± SE (*** P < 0.001). 
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After stimulation of AtT20 cells with 10 μg/ml, 25 μg/ml, 50 μg/ml and 100 μg/ml of iE-
DAP and MDP for 48 hours and removal of its supernatant, the RIA (Radioimmunoassay) 
technique was used to determine the concentration of hormones, in this particular case 
the concentration of ACTH. The ligands of NOD1 (iE-DAP) and NOD2 (MDP) clearly 
decreased the ACTH levels when compared to basal levels of the unstimulated samples 
(Fig. 18).  
 
Fig. 18: ACTH levels in with NOD ligands treated AtT20 cells assessed by Radioimmunoassay. 
AtT20 cells were left stimulated or unstimulated for 48 hours, followed by the RIA 
measurement. Values are presented in percentage of control and as the mean ± SE (* P < 0.05 
and *** P < 0.001). 
 
4.2.2 ACTH secretion of normal rat pituitaries is not influenced by NOD receptors 
Rat pituitary cells were handled as described in chapter 3.3.1 and stimulated for 24 and 
48 hours in a similar manner as AtT20 cells to examine the effect of NOD receptor 
activation on ACTH secretion. After the stimulation time elapsed, the supernatant was 
removed and evaluated by RIA. CRH and Forskolin are well-known activators of ACTH 
secretion in corticotropic cells. Therefore, as a control of potent cells, 100 nM of CRH and 
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5 μM of Forskolin were also included in the experiment. The results demonstrate that 
NOD receptors have no impact on ACTH secretion in normal rat pituitaries (Fig. 19 a + 
b).  
 
Fig. 19 a+b: ACTH secretion in normal rat pituitaries. a) ACTH levels assessed by RIA after 24 hours of 
stimulation with 100 nM CRH, 5 μM Forskolin, 5 μg/ml, 10 μg/ml, 30 μg/ml and 50 μg/ml of iE-DAP and MDP; 
b) ACTH levels assessed by RIA after 48 hours of stimulation with 100 nM CRH, 5 μM Forskolin, 5 μg/ml, 10 
μg/ml, 30 μg/ml and 50 μg/ml of iE-DAP and MDP. Values are presented in percentage of control and as the 
mean ± SE (*** P < 0.001). 
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To sum up, it could be said that on the one hand NOD receptor activation suppressed 
POMC promoter activity and subsequently the ACTH secretion in AtT20 cells, but on the 
other hand no changes could be observed in ACTH secretion in normal rat pituitaries 
after treatment with the specific ligands of NOD1 and NOD2. 
4.3 NOD receptors are involved in cell proliferation 
Whereas in immune cells NOD1 and NOD2 act as sensors of bacterial invasion [126], 
their role in tumor cells is largely unknown. Since it appears that NOD signaling is active 
in the ACTH secreting cell line AtT20 and in pituitary adenomas, the effect of these 
intracellular receptors on proliferation was further investigated. 
4.3.1 NOD ligands increase proliferation in AtT20 cells 
Both NOD1 ligand iE-DAP and NOD2 ligand MDP stimulated the proliferation of AtT20 
cells. The cells were treated with 10 μg/ml, 30 μg/ml and 50 μg/ml of each stimulus for 
48 hours, and the effect was carried out by the WST-1 proliferation assay. Both ligands 
significantly increased the proliferation in AtT20 cells, shown in figure 20. 
 
Fig. 20: AtT20 WST-1 
proliferation assay. Cell 
proliferation was examined in 
untreated cells and treated 
cells with 10 μg/ml, 30 μg/ml 
and 50 μg/ml of both, iE-DAP 
and MDP. Proliferation was 
measured 48 hours after 
treatment by WST-1 assay. 
Values are presented in 
percentage of control and as 
the mean ± SE (*** P < 0.001). 
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As already described in the introduction, the PI3K pathway plays crucial roles in many 
cellular processes, including proliferation. Proliferation can be suppressed by the PI3K 
inhibitors Wortmannin and LY294002 [127]. Thus, it would be interesting to elucidate 
the role of PI3K in AtT20 cells` proliferation. As the proliferation is not dose-dependent 
but the 30 μg/ml concentration of each stimulus seemed to be the most suitable one, this 
concentration was chosen for further experiments. In the first set of the experiment the 
cells were treated with both ligands. Additionally, some of them were left untreated to 
show the basal condition. The second set was treated the same, but additionally with 5 
μM of the PI3K inhibitor LY294002. As represented in figure 21, the proliferative effect 
induced by the ligands was inhibited.  
 
 
Fig. 21: Effect of PI3K inhibitor 
LY294002 on AtT20 cells. Cells were 
pre-treated with serum-free medium 
and 5 μM of LY294002 for one hour 
and then stimulated with iE-DAP (30 
μg/ml) and MDP (30 μg/ml) for 48 
hours. Proliferation was measured by 
WST-1 assay. Values are presented in 
percentage of control and as the 
mean ± SE (*** P < 0.001). 
 
 
In order to complete and circumstantiate the result obtained with the LY294002 
inhibitor, a second PI3K inhibitor was included in the experiments. The cells were 
treated with 1 nM Wortmannin to explore and confirm the effect on AtT20 cells` 
proliferation. As expected, Wortmannin also blocked NOD ligands induced proliferation 
in AtT20 cells (Fig. 22). 
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Fig. 22: Effect of PI3K inhibitor 
Wortmannin on AtT20 cells. Cells 
were pre-treated with serum-free 
medium and 1 nM of Wortmannin 
for one hour and then stimulated 
with iE-DAP (30 μg/ml) and MDP 
(30 μg/ml) for 48 hours. 
Proliferation was measured by 
WST-1 assay. Values are 
presented in percentage of 
control and as the mean ± SE (* P 
< 0.05 and *** P < 0.001). 
 
 
As NF-κB (nuclear factor-κB) is another important pathway related to proliferation, the 
inhibitor Caffeic acid phenethyl ester (CAPE) was also used. CAPE is an anti-
inflammatory component of propolis (honeybee resin) and reported to be a specific 
inhibitor of NF-κB [128]. As depicted in Fig. 23, 25 μg/ml of CAPE suppressed the 
proliferation induced by NOD ligands in AtT20 cells.  
 
 
 
Fig. 23: Effect of NF-κB inhibitor 
CAPE on AtT20 cells. Cells were 
pre-treated with serum-free 
medium and 5 μg/ml of CAPE for 
one hour and then stimulated 
with iE-DAP (30 μg/ml) and 
MDP (30 μg/ml) for 48 hours. 
Proliferation was measured by 
WST-1 assay. Values are 
presented in percentage of 
control and as the mean ± SE 
(*** P < 0.001). 
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4.3.2 NOD ligands increase proliferation in pituitary adenomas 
Prompted by the increased NOD mRNA levels in a subset of pituitary adenomas and the 
induced proliferation in AtT20 cells, the effect of NOD activation on the proliferation of 
pituitary adenomas was examined. Prolactinoma, non functioning pituitary adenoma, 
somatotropinoma and corticotropinoma cells were prepared according to chapter 3.3.1 
and 48 hours after preparation, the stimulation experiment was started. The experiment 
was performed with the same parameters as for AtT20 cells. Proliferation triggered by 
the NOD ligands significantly increased in all pituitary adenomas, but generally slightly 
lower than in AtT20 cells. (Fig. 24 a-d).  
 
 
Fig. 24 a: Prolactinoma WST-1 
proliferation assay. Cell 
proliferation was examined in 
untreated cells and treated cells 
with 10 μg/ml, 30 μg/ml and 50 
μg/ml of both, iE-DAP and MDP. 
Proliferation was measured 48 
hours after treatment by WST-1 
assay. Values are presented in 
percentage of control and as the 
mean ± SE (* P < 0.05). 
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Fig. 24 b: Non functioning 
pituitary adenoma [3H]-thymidine 
incorporation assay. Cell 
proliferation was examined in 
untreated cells and treated cells 
with 10 μg/ml, 30 μg/ml and 50 
μg/ml of both, iE-DAP and MDP. 
Proliferation was measured 48 
hours after treatment by WST-1 
assay. Values are presented in 
percentage of control and as the 
mean ± SE (* P < 0.05). 
 
 
 
 
Fig. 24 c: Somatotropinoma WST-
1 proliferation assay. Cell 
proliferation was examined in 
untreated cells and treated cells 
with 10 μg/ml, 30 μg/ml and 50 
μg/ml of both, iE-DAP and MDP. 
Proliferation was measured 48 
hours after treatment by WST-1 
assay. Values are presented in 
percentage of control and as the 
mean ± SE (* P < 0.05). 
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Fig. 24 d: Corticotropinoma WST-1 proliferation assay. Cell 
proliferation was examined in untreated cells and treated cells 
with 10 μg/ml, 30 μg/ml and 50 μg/ml of both, iE-DAP and 
MDP. Proliferation was measured 48 hours after treatment by 
WST-1 assay. Values are presented in percentage of control 
and as the mean ± SE (* P < 0.05). 
In the non functioning pituitary adenomas only the NOD1 ligand iE-DAP in a 
concentration of 10 μg/ml and 30 μg/ml seemed to be not functional. Unfortunately, due 
to lack of material, the proliferative effect of NOD ligands on tyreotropinomas could not 
be investigated. The most important effect to this study is reflected by the Cushing`s 
associated pituitary adenomas, as this work is focused on the corticotroph cell line 
AtT20, which is used as a model in this study and also widely used to investigate ACTH 
biosynthesis and secretion. 
These results suggest that NOD receptor activation stimulates proliferation and survival 
in pituitary cells and in pituitary adenomas. The PI3K/AKT and NF-κB pathway may act 
as downstream mediators on the proliferation promoting effects of NOD signaling 
pathway in AtT20 cells. Thus, the NOD receptor signaling pathway may specifically 
affect the viability of pituitary tumor cells, and the ligands of NOD may stimulate 
pituitary tumor cell expansion. 
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4.4 Cell cycle regulation by NOD receptors 
Cell cycle progression of mammalian cells is controlled by a series of cyclin-dependent 
kinases, CDKs, and their activating cyclin subunits [50]. This process is often disturbed 
in tumors including pituitary adenomas [129-133]. Based on the findings that treatment 
with NOD ligands result in increased proliferation, the next step was to test whether 
NOD signaling participates in the regulation of cell cycle in AtT20 cells. The G1 to S-
phase transition is often disrupted in cancers due to its intimate function in the 
integration of growth factor signals with the cell cycle network. Keeping this in mind, I 
have started to perform experiments to analyze the activity of individual proliferative 
signaling molecules through cell cycle. The protein extraction was carried out 24 hours 
after stimulation. Of the early G1 regulatory molecules, a slight increase of CDK4 protein 
expression after treatment with NOD ligands or overexpression of NOD2 could be 
observed (Fig. 25 a). As the kinase is completely inactive without its cyclin partner, the 
protein levels of Cyclin D1 and Cyclin D3, as corresponding CDK4 partners, were 
explored. Consequentially, their protein expression was also upregulated (Fig. 25 b). 
 
 
 
 
 
 
 
 
 
Fig. 25 a: Protein expression of CDK4 in AtT20 cells. Depicted are the increased 
protein levels of CDK4 after treatment with 30 μg/ml of iE-DAP and MDP for 24 
hours, and after overexpression of NOD2. Western Blot bands were converted in 
numeric values by ImageJ and are presented in percentage of control. 
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Fig. 25 b: Protein expression of Cyclin D1 and Cyclin D3 in AtT20 cells. Depicted are the 
increased protein levels after treatment with 30 μg/ml of iE-DAP and MDP for 24 hours. 
Western Blot bands were converted in numeric values by ImageJ and are presented in 
percentage of control. 
 
Additionally, the expression of CDK2 and Cyclin E, which are involved in the late G1 to S-
phase progression, were also investigated. Unlike the CDK4 protein levels, the CDK2 
protein expression was considerably increased after treatment with 30 μg/ml of iE-DAP 
and MDP for 24 hours as shown in figure 26 a. 
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Fig. 26 a: Protein expression of CDK2 in AtT20 cells. 
Depicted are the increased protein levels after treatment 
with 30 μg/ml of iE-DAP and MDP for 24 hours. Western 
Blot bands were converted in numeric values by ImageJ 
and are presented in percentage of control. 
 
 
 
 
 
The protein expression of Cyclin E, which is known as the regulatory partner of CDK2, 
was also markedly elevated after treatment with NOD ligands on exactly the same 
conditions (Fig. 26 b).  
 
 
 
Fig. 26 b: Protein expression of Cyclin E in AtT20 cells. 
Depicted are the increased protein levels after treatment 
with 30 μg/ml of iE-DAP and MDP for 24 hours. Western 
Blot bands were converted in numeric values by ImageJ and 
are presented in percentage of control. 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
B
as
al
iE
-D
A
P
 3
0
μ
g
M
D
P
 3
0
μ
g
C
D
K
2
/β
-a
c
ti
n
CDK2 
β-actin 
CDK2 
β-actin 
0
20
40
60
80
100
120
140
160
180
200
B
as
al
iE
-D
A
P
 3
0
μ
g
M
D
P
 3
0
μ
g
C
y
c
lin
 E
/β
-a
c
ti
n
Cyclin E 
β-actin 
66 
 
As described in the introduction, the Rb (retinoblastoma) is a major component of the 
cell cycle. Therefore the protein level of phosphorylated Rb was explored. AtT20 cells 
were stimulated with 30 μg/ml of iE-DAP and MDP for 24 hours and the activation 
status of Rb was assessed. Simultaneously to the phosphorylation state at Ser780, the 
phosphorylation levels at the Ser795 residue were also examined. In figure 27 it is 
shown, that NOD ligands considerably increased the phosphorylation levels of this 
important cell cycle component at both residues, so that the cells could proceed through 
the cell cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27: Rb activation in AtT20 cells. Shown are the increased phosphorylation levels after 
treatment with 30 μg/ml of iE-DAP and MDP for 24 hours. Western Blot bands were 
converted in numeric values by ImageJ and are presented in percentage of control. 
 
Among the Rb, there are other important regulators of cell cycle like GSK-3β 
(glycogen synthase kinase-3β) and the members of the FOXO family. Thus, it was 
important to consider their role in this context. Both NOD ligands increased the 
phosphorylation of GSK-3β, even though the phosphorylation induced by iE-DAP 
was weak (Fig. 28).   
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Fig. 28: GSK-3β activation in AtT20 cells. Presented are the 
increased phosphorylation levels after treatment with 30 
μg/ml of iE-DAP and MDP for 24 hours. Western Blot bands 
were converted in numeric values by ImageJ and are 
presented in percentage of control. 
 
 
 
 
In recent years FOXO family members have emerged as key players in controlling cell 
cycle. FOXO is known to induce cell cycle arrest through p27, a member of the KIP 
family, which inhibits CDK2 activity and therefore blocks the cell cycle progression at 
the G1/S-phase. FOXO, as well as GSK-3β, become inactive after phosphorylation. Figure 
29 indicates the enhanced levels of phosphorylated FOXO after NOD ligands stimulation.  
 
 
 
Fig. 29: FOXO phosphorylation in AtT20 cells. Depicted are the 
increased phosphorylation levels after treatment with 30 μg/ml 
of iE-DAP and MDP for 24 hours. Western Blot bands were 
converted in numeric values by ImageJ and are presented in 
percentage of control. 
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Consequently, I also had a look on the cyclin-dependent kinase inhibitors p27 and p21, 
respectively. Both inhibitors fulfill their tasks in the late G1/S-phase by inhibiting the 
CDK2 activity. After all, it was not astonishing that their quantity was reduced. Western 
Blot analysis discovered low levels of p21 upon stimulation with the ligands for 24 
hours (Fig. 30).  
 
 
 
 
Fig. 30: Downregulation of cyclin-dependent kinase 
inhibitor p21 in AtT20 cells. Depicted are the reduced 
protein levels after treatment with 30 μg/ml of iE-DAP and 
MDP for 24 hours. Western Blot bands were converted in 
numeric values by ImageJ and are presented in percentage 
of control. 
 
 
 
 
 
In the case of p27, overexpression of NOD2 was additionally included in the experiment 
and mRNA levels of p27 were established by RT-PCR (Fig. 31).   
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Fig. 31: Downregulation of cyclin-dependent kinase inhibitor p27 in AtT20 cells. 
Depicted are the reduced mRNA levels after treatment with 30 μg/ml of iE-DAP and 
MDP for 24 hours and after overexpression of NOD2. RT-PCR bands were converted in 
numeric values by ImageJ and are presented in percentage of control. 
 
Taken together, this data support the theory that NOD receptors have a strong influence 
on cell cycle progression, especially on cell cycle components regulating the G1/S-phase 
transition. They target mechanisms of cell proliferation and cell cycle, and this could 
play a role in tumor transformation and survival of pituitary cells. 
4.5 A series of biochemical apoptosis events are negatively regulated by NOD 
receptors 
Apoptosis is a fundamental biological process of all multicellular organisms and plays an 
important role to the cells` fate. The mechanisms that direct a cellular decision whether 
to live or to die are complex and tightly regulated by abundance of molecules with 
distinct roles in the signaling process. Here it is considered how NOD receptors affect 
this process. 
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The tumor suppressor p53 acts as a guardian, preventing cells from malignant 
transformation by responding to a variety of signals and triggering cell cycle arrest, 
apoptosis and senescence. Inactivation of p53 occurs in over half of all human tumors, 
underscoring the importance of this gene to the pathogenesis of cancer [134]. The 
function of p53 relies on its ability to induce expression of pro-apoptotic genes including 
BAX, or to act as an inhibitor of cell cycle by inducing p21 mediated cell cycle arrest 
[135]. I have already described the effects of NOD1/NOD2 on p21 protein expression. 
Thus, this chapter will focus on the apoptotic effects of p53. To determine whether there 
is an involvement of NOD receptors in modulating the transcriptional activity of p53, the 
luciferase reporter gene assay was performed as described in chapter 3.5.2. AtT20 cells 
were stimulated with 30 μg/ml of iE-DAP and MDP for 24 hours. The experiment 
revealed a significant inhibition of p53 luciferase activity (Fig. 32). 
 
 
 
 
Fig. 32: NOD ligands decrease p53 luciferase 
activity in AtT20 cells. AtT20 cells were 
transfected with p53-LUC plasmid and 
stimulated with 30 μg/ml of iE-DAP and MDP. 
After 24 hours, luciferase activity was 
measured. Values are presented in percentage 
of control and as the mean ± SE (* P < 0.05). 
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The cells were additionally transfected with control plasmid and NOD2 overexpression 
plasmid and stimulated with 30 μg/ml of MDP for 24 hours. Matching the data with the 
stimulus, the overexpression of NOD2 also decreased the transcriptional activity of p53 
(Fig. 33).  
 
 
 
Fig. 33: Decreased p53 luciferase activity in 
NOD2 overexpressed AtT20 cells. AtT20 
cells were transfected with control plasmids 
or NOD2 expression vector along with p53-
LUC with or without 30μg/ml of MDP. 24 
hours post-transfection, luciferase activity 
was measured. Values are presented in 
percentage of control and as the mean ± SE 
(* P < 0.05 and *** P < 0.001). 
 
 
 
It is already well known that BAX is a main downstream target of p53. For this reason 
the connection between p53 and BAX was evaluated. BAX functions as a pro-apoptotic 
protein and belongs to the BCL-2 gene family [136]. After stimulation of AtT20 cells for 
24 hours with NOD ligands and overexpression of NOD2, the protein expression of BAX 
was investigated. Figure 34 illustrates the reduced protein expression of BAX, assessed 
by Western Blot. 
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Fig. 34: Downregulation of BAX protein expression in AtT20 cells. Depicted are 
the reduced protein levels after treatment with 30 μg/ml of iE-DAP and MDP 
for 24 hours and after overexpression of NOD2. Western Blot bands were 
converted in numeric values by ImageJ and are presented in percentage of 
control. 
 
PTEN, another important tumor suppressor is frequently mutated or deleted in several 
types of cancers and known as a further guardian for a cell to not take the path to cancer 
[67, 68]. Recently a mechanistic link between PTEN and p53 has been established. As 
PTEN is frequently mutated in tumors and is able to anagonize the PI3K signaling, the 
phosphorylation level of PTEN was measured by Western Blot after stimulation with 30 
μg/ml of iE-DAP and MDP for 24 hours. An obvious inhibition could be demonstrated 
(Fig. 35). 
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Fig. 35: Downregulation of phosphorylated PTEN in AtT20 
cells. Shown are the reduced phosphorylation levels after 
treatment with 30 μg/ml of iE-DAP and MDP for 24 hours. 
Western Blot bands were converted in numeric values by 
ImageJ and are presented in percentage of control. 
 
 
 
 
The XIAP (X-linked Inhibitor of Apoptosis Protein) protein is a member of the inhibitor 
of apoptosis family of proteins (IAP) and able to stop apoptotic cell death [137]. AtT20 
cells were stimulated with 30 μl/mg of iE-DAP and MDP for 24 hours. Proteins were 
extracted and Western Blot analysis performed (Fig. 36).  
 
 
 
Fig. 36: Upregulation of XIAP protein expression in AtT20 
cells. Illustrated are the increased protein levels after 
treatment with 30 μg/ml of iE-DAP and MDP for 24 hours. 
Western Blot bands were converted in numeric values by 
ImageJ and are presented in percentage of control. 
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The JNK (c-Jun N-terminal Kinase) protein and the AP-1 (activator protein 1) 
transcription factor are also linked to apoptosis. JNKs mostly target transcription factors 
and one of these factors is AP-1. Thus, the phosphorylation status of JNK was analyzed 
using the Western Blot technique. AtT20 cells were stimulated in time-dependent 
manner with 30 μl/mg of iE-DAP and MDP. The JNK phosphorylation levels were 
strikingly decreased when compared to basal levels (Fig. 37).  
 
 
 
 
 
 
 
 
 
 
Fig. 37: Downregulation of JNK phosphorylation in AtT20 cells. Illustrated are the 
decreased phosphorylation levels in time-dependent manner after treatment 
with 30 μg/ml of iE-DAP and MDP. Western Blot bands were converted in 
numeric values by ImageJ and are presented in percentage of control. 
AP-1 is a transcription factor, which regulates gene expression in response to a variety 
of stimuli and controls a range of cellular processes including apoptosis [138]. The 
transcriptional activity of AP-1, measured by luciferase gene reporter assay, was 
significantly inhibited (Fig. 38). 
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Fig. 38: NOD ligands decrease AP-1 luciferase 
activity in AtT20 cells. AtT20 cells were 
transfected with AP-1-LUC plasmid and 
stimulated with 30 μg/ml of iE-DAP and MDP. 
After 24 hours, luciferase activity was measured. 
Values are presented in percentage of control and 
as the mean ± SE (*** P < 0.001). 
 
 
Taken together, the results presented in this chapter suggest that the AtT20 pituitary 
cells are driven towards expansion and survival, rather than to apoptosis. The results 
clearly demonstrate that NOD receptors don`t induce cell death but might support 
cancer development. 
4.6 NOD1 and NOD2 signaling targets related to survival 
As described in the introduction, there are many signaling pathways affected by NOD 
receptors. The most investigated pathway in response to NOD ligands is the NF-κB 
pathway. This evolutionary conserved pathway is of major importance due to the fact 
that NF-κB regulates many biological processes including survival. The pathway is also 
known to act contrary to apoptosis. The PI3K pathway members and the MAPK 
members, in particular the ERK module and the P38 group, represent further pathways 
critical to many cellular events and are also mostly associated with survival and 
proliferation. Therefore, this last chapter of the results part will focus on the pathways 
related to survival and how they are affected by NOD receptor activation. 
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4.6.1 NOD receptor activation induce NF-κB upregulation 
AtT20 cells were transfected with κB-LUC plasmid and stimulated with 30 μg/ml of iE-
DAP and MDP. 6 hours post-transfection, luciferase activity was measured. Both NOD 
ligands significantly induced NF-κB activation (Fig. 39). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 39: NF-κB is upregulated by NOD receptors in AtT20 cells. AtT20 cells 
were transfected and stimulated for 6 hours with κB-LUC plasmid and 30 
μg/ml of iE-DAP and MDP. Luciferase activity measurement was followed. 
Values are presented in percentage of control and as the mean ± SE (* P < 
0.05 and *** P < 0.001). 
 
By protein extraction and Western Blot analysis the phosphorylation levels of NF-κB 
have been investigated as well. AtT20 cells were stimulated for 5 minutes, 10 minutes, 
20 minutes, 30 minutes and 60 minutes with 30 μg/ml of iE-DAP and MDP to verify the 
phosphorylation status. At each point of this time curve the NOD ligands increased NF-
κB phosphorylation (Fig. 40). 
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Fig. 40: NF-κB phosphorylation by NOD receptors. Illustrated are the increased 
phosphorylation levels in time-dependent manner after treatment with 30 μg/ml 
of iE-DAP and MDP. Western Blot bands were converted in numeric values by 
ImageJ and are presented in percentage of control. 
 
BCL-2 is the prototype of a family of proteins, which can be either pro-apoptotic or anti-
apoptotic. It is already shown that NF-κB transcriptionally regulates BCL-2 and that 
increased levels of BCL-2 make cancer cells more resistant to apoptotic effects [139]. In 
this experiment only the effect of the NOD2 overexpression was evaluated. AtT20 cells 
were transfected with the NOD2 overexpression plasmid for 24 hours followed by the 
protein extraction and Western Blot analysis. The protein expression was elevated in 
samples transfected with the overexpression plasmid NOD2 (Fig. 41).  
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Fig. 41: Upregulation of BCL-2 by NOD2 overexpression. 
AtT20 cells were transfected with control and NOD2 
overexpression plasmid, and proteins were extracted 24 
hours post-transfection. Western Blot bands were 
converted in numeric values by ImageJ and are presented 
in percentage of control. 
 
 
 
Furthermore, after transfecting the AtT20 cells with specific siRNA targeting NOD2 and 
a non-targeting siRNA (Si Control) for 24 hours, the upregulation of BCL-2 could be 
reversed, proving the specificity of the experiments (Fig. 42). 
 
 
 
Fig. 42: Downregulation of BCL-2 protein expression by 
silencing NOD2 in AtT20 cells. Cells were transfected with 
siRNA for NOD2 and non-targeting siRNA, Si Control. 24 hours 
post-transfection, proteins were extracted. Western Blot bands 
were converted in numeric values by ImageJ and are presented 
in percentage of control. 
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4.6.2 Phosphorylation of PI3K pathway members induced by NODs 
As already mentioned, the PI3K pathway and its members play a crucial regulatory role 
in many cellular processes. As till now the results of the study show increased 
proliferation and support the idea that the whole system is pushed towards survival, it is 
interesting to evaluate the contribution of PI3K pathway and its members. AtT20 cells 
were stimulated and harvested after various periods to observe the changes in the 
phosphorylation status of AKT. As shown in figure 43 the NOD ligands increased AKT 
phosphorylation on the Ser473 residue at all times.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 43: Phosphorylation levels of AKT Ser473 by NOD receptors. Illustrated are the 
increased phosphorylation levels in time-dependent manner after treatment with 30 
μg/ml of iE-DAP and MDP. Western Blot bands were converted in numeric values by 
ImageJ and are presented in percentage of control. 
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Specific siRNA against NOD1 and NOD2 as well as a non-targeting siRNA as a control 
were used to knock down the gene expression of NOD receptors. After transfecting 
AtT20 cells with siRNA for NOD1 and NOD2 and si Control, the proteins were extracted 
and the phosphorylation state of AKT was carried out by Western Blot analysis. 
Interestingly, knock down of NOD1 and NOD2 decreased phosphorylation of AKT on 
both, Ser473 and Thr308 residues, when compared to si Control (Fig. 44 a +b). 
 
 
 
 
 
 
 
 
 
 
Fig. 44 a: Inhibition of AKT Ser473 phosphorylation by silencing NOD1 and NOD2 in 
AtT20 cells. Cells were transfected with siRNA for NOD1, NOD2 and non-targeting 
siRNA, Si Control. The proteins were extracted 24 hours post-transfection. Western Blot 
bands were converted in numeric values by ImageJ and are presented in percentage of 
control. 
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Fig. 44 b: Inhibition of AKT Thr308 phosphorylation by silencing NOD1 and NOD2 in 
AtT20 cells. Cells were transfected with siRNA for NOD1, NOD2 and non-targeting 
siRNA, Si Control. The proteins were extracted 24 hours post-transfection. Western Blot 
bands were converted in numeric values by ImageJ and are presented in percentage of 
control. 
Another downstream component of the PI3K/AKT pathway is the serine-threonine 
kinase mTOR, a key regulator of cell growth and survival [118]. NOD receptor activation 
by the ligands markedly induced the phosphorylation at residue Ser2448 (Fig. 45).  
 
 
Fig. 45: Phosphorylation of mTOR at Ser2448 
residue in AtT20 cells. Depicted are the increased 
phosphorylation levels after treatment with 30 
μg/ml of iE-DAP and MDP for 24 hours. Western 
Blot bands were converted in numeric values by 
ImageJ and are presented in percentage of control. 
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Increased levels of mTOR led to an enhanced expression surrounding Ser792 of Raptor 
in the mTORC1 protein complex (Fig. 46).   
 
 
 
Fig. 46: Phosphorylation of Raptor at Ser792 residue in 
AtT20 cells. Depicted are the increased phosphorylation 
levels after treatment with 30 μg/ml of iE-DAP and MDP for 
24 hours. Western Blot bands were converted in numeric 
values by ImageJ and are presented in percentage of 
control. 
 
 
The subsequent event of the mTORC1 complex activation is the phosphorylation of its 
substrate, the p70S6K (p70 ribosomal protein S6 kinase) at the Thr389 residue (Fig. 47).  
 
 
 
Fig. 47: Phosphorylation of p70S6K at Thr389 residue in 
AtT20 cells. Depicted are the increased phosphorylation 
levels after treatment with 30 μg/ml of iE-DAP and MDP for 
24 hours. Western Blot bands were converted in numeric 
values by ImageJ and are presented in percentage of 
control. 
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4.6.3 NOD receptor activation affects members of the MAPKs 
 
To determine whether NOD receptors affect MAPK pathways, the activation state of the 
ERK1/2 module and P38 MAPK was investigated. The phosphorylation levels were 
evaluated after treatment with 30 μg/ml of iE-DAP and MDP at different times. NOD 
ligands significantly increased phosphorylation of ERK1/2 when compared to 
unstimulated basal levels (Fig. 48). 
 
 
 
 
Fig. 48: Increased phosphorylation of ERK1/2 by NOD receptors. Illustrated are the increased 
phosphorylation levels in time-dependent manner after treatment with 30 μg/ml of iE-DAP 
and MDP. The upper band shows the ERK1 (p44) protein and the lower band shows the ERK2 
(p42) protein. Western Blot bands were converted in numeric values by ImageJ and are 
presented in percentage of control. 
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Just as the ERK1/2, the phosphorylation state of P38 MAPK showed exactly the same 
pattern, which means that NOD receptors activation induced phosphorylation of P38 
significantly (Fig. 49).  
 
Fig. 49: Increased phosphorylation of P38 by NOD receptors. Illustrated are the increased 
phosphorylation levels in time-dependent manner after treatment with 30 μg/ml of iE-DAP 
and MDP. Western Blot bands were converted in numeric values by ImageJ and are 
presented in percentage of control. 
 
Altogether the outcomes of this last chapter clearly show that, besides the activation of 
NF-κB, the PI3K/AKT pathway is also affected by NOD receptors activation and is 
definitely an important downstream target of these molecules. Moreover the findings 
suggest that NOD signaling may also modulate MAPK levels. All in all the results can be 
connected to increased proliferation and survival of pituitary tumoral cells AtT20. 
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5. Discussion 
 
In terms of pathophysiology of the pituitary gland, epidemiologic analyses have 
identified a much higher incidence of pituitary tumors than previously thought. Pituitary 
tumors are reported to account 10% - 15% of all intracranial tumors. Many pituitary 
tumors are silent and not frequently diagnosed, while others may be life-threatening. 
These tumors cause compression of intracranial structures and hormone 
hypersecretion. Little is known about the precise environmental and genetic factors 
leading to their development, so preventive measures are unavailable.  
The known physiological significance of NOD receptors lies primarily in their roles in 
host defense against microbial infections. Many inflammatory and non-inflammatory 
disease processes can be attributed to dysregulated NOD receptor signaling. Dysreglated 
NOD2 signaling can lead to either gain of function (constitutive NF-κB activation) or loss 
of function (defective NF-κB activation) phenotypes. While gain of function mutations 
have been described in Blau syndrome, loss of function mutations have been associated 
with Crohn`s Disease [140-141]. In addition, abnormalities in NOD1 function might lead 
to the development of chronic infection with Helicobacter pylori and to the subsequent 
development of peptic-ulcer disease and gastric carcinoma [142]. Chronic inflammation 
plays a multifaceted role in carcinogenesis. Mounting evidence suggests that persistent 
inflammation functions as a driving force on the way to cancer. Approximately 25% of 
all cancers are somehow associated with chronic infection and inflammation [143]. As 
mentioned in the introduction, there is already strong evidence that these two 
intracellular immune receptors are involved in tumorigenesis. NOD1 signaling pathway 
regulates inflammation-mediated colon cancer and tumor growth in breast cancer, 
whereas NOD2 receptors are involved in promoting growth and survival of human 
colonic carcinomas [76, 77, 78]. The possible mechanisms, by which inflammation can 
contribute to tumorigenesis imply a distinct network of intracellular signaling 
molecules, including upstream kinases and transcription factors, which facilitate tumor 
promotion and progression by increasing proliferation, survival and growth and 
inducing resistance to apoptosis.  
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5.1 Expression of NOD immune receptors in the pituitary gland 
The starting point of the whole thesis and the basis for all following experiments was the 
demonstration that NOD immune receptors are expressed in the pituitary gland and 
ACTH secreting cell line AtT20, which has been used as a model. Immunohistochemistry 
and RT-PCR experiments, carried out as part of my diploma thesis, clearly revealed the 
expression of both NOD receptors in AtT20 cells. Moreover, the expression of NOD1 and 
NOD2 was also detected in normal human pituitaries. These findings suggest that the 
intracellular immune receptors NOD1 and NOD2 are functional in the pituitary gland. To 
explore the possible correlation between the presence of pituitary adenomas and the 
expression of these two intracellular receptors NOD1 and NOD2, samples of four normal 
pituitaries and thirty-eight different human pituitary adenomas were investigated by 
using the RT-PCR method. Interestingly, in a considerable proportion of the pituitary 
adenomas studied, increased mRNA levels of NOD1 and NOD2 were observed, when 
compared to normal pituitaries. Hence, at that point it could be speculated that NOD 
expression is involved in pituitary tumor progression. 
5.2 Effects on hormone production  
After the first evidence of functional NOD receptors in the pituitary gland the question 
raised, whether there was an impact on hormone production. The AtT20 murine 
corticotroph cell line is one of the most studied pituitary cell lines and is widely used as 
a model to understand the physiology and pathology of corticotrophs` action. POMC 
(Proopiomelanocortin) is synthesized by corticotroph cells and processed to ACTH, 
which stimulates the adrenal cortex. More specifically, it stimulates the secretion of 
glucocorticoids. The glucocorticoids in turn exert a classical negative feedback on the 
Hypothalamic-Pituitary-Adrenal (HPA) axis. Disturbance of this system causes various 
endocrine syndromes. One of the most severe is the Cushing`s Syndrome, which results 
from chronic exposure to glucocorticoids. A Cushing`s Syndrome develops after 
transformation of normal corticotroph cells of the anterior pituitary lobe of a ACTH-
secreting pituitary tumor. The transformed cells grow and develop into an ACTH-
secreting adenoma. At the moment there is no effective pharmacological therapy to 
control ACTH over-secretion by pituitary tumors. Positive and negative regulation of the 
POMC gene has been described and shown to be mediated by several transcription 
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factors, such as AP-1, NF-κB and Nur elements [144-146]. POMC transcriptional activity 
was lowered in AtT20 cells after stimulation with NOD1 ligand, iE-DAP, and NOD2 
ligand, MDP, as well as by NOD2 overexpression. Corresponding to this inhibition was 
the elevated activation of NF-κB, induced by NOD receptors. This result fits with the 
recent discovered mechanism, by which an inhibition of NF-κB DNA-binding activity is 
required for the transcriptional activation of POMC gene by CRH. Thus, the increased 
activity of NF-κB is associated with decreased transcriptional activity of the POMC gene. 
Furthermore, it has been well shown that POMC gene is associated with activation of the 
AP-1 transcription factor [147]. Two Nur DNA binding sites have been identified on the 
POMC promoter. The distal Nur response element is NurRE and plays a major role in 
mediating stimulation through CRH [125]. Both transcription factors, AP-1 and NurRE, 
were downregulated in AtT20 cells, either by NOD ligands or by NOD2 overexpression. 
NOD ligands are involved in the regulation of POMC through a mechanism implying 
other transcription factors. Consequently, ACTH production was low after treatment 
with the ligands of NOD1 and NOD2 in AtT20 cells. The question arose, whether the NOD 
receptors also influence hormone production in primary cell cultures of normal rat 
pituitaries. The idea suggests itself, that the effect of NOD ligands seen in AtT20 cells 
also takes place in normal rat pituitaries. The next logical step was to evaluate the ACTH 
levels in normal rat pituitary cells treated with NOD ligands. As the normal rat 
pituitaries showed no changes in ACTH levels upon iE-DAP and MDP treatment, it could 
be speculated that the NOD ligands target the pathophysiological side by affecting just 
tumoral cells, at least in terms of ACTH secretion. This suggests that NOD receptors 
could be a possible pharmaceutical target. 
5.3 Proliferation and Survival 
5.3.1 Proliferation 
 
Dysregulation of various cell cycle pathways has been reported to be a frequent event in 
pituitary tumors [36, 43, 45, 131]. Uncontrolled cellular proliferation is known to 
consequently lead to tumor development and is in most cases associated with cell cycle 
dysregulation. Normal mammalian cellular proliferation is monitored at each phase of 
the cell cycle by a cyclically operating biochemical machinery, constructed from a set of 
interacting proteins that induce and coordinate proper progression through the cell 
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cycle. This includes cyclins and cyclin-dependent kinases (CDKs), which promote cell 
cycle progression, and their inhibitors that oppose cell proliferation. Pituitary adenomas 
are generally associated with extremely low proliferative rates, especially when 
compared to AtT20 cells, which are known to be fast reproducing cells. 
In AtT20 cells as well as in pituitary adenomas, NOD receptor activation led to increased 
proliferation levels. The cell proliferation was also assessed by using the PI3K inhibitors, 
Wortmannin and LY294002, molecules that disrupt the ATP binding pocket of PI3K and 
PI3K like enzymes. While Wortmannin is an irreversible inhibitor, LY294002 is a 
competitive inhibitor [127]. The PI3K inhibitors, LY294002 and Wortmannin, as well as 
the NF-κB inhibitor CAPE (Caffeic acid phenethyl ester) have been used to verify the 
involvement of these two pathways in the proliferative effect of NOD stimulation. Since 
all three inhibitors strongly inhibited the mitogenic effect, both pathways may be 
involved in the proliferation promoting effects of NOD signaling pathways in AtT20 cells. 
The roles of PI3K/AKT pathway in NF-κB dependent gene expression are controversial. 
It has been shown that the PI3K/AKT pathway can positively or negatively regulate NF-
κB expression [119,148]. In addition, it still remains to be clarified whether NF-κB could 
act downstream of PI3K/AKT signaling. 
NOD receptors activation clearly affects intrinsic mechanisms controlling cell 
proliferation and the cell cycle which in turn can contribute to neoplastic 
transformation. Furthermore, NOD receptors signaling may specifically affect the 
survival of pituitary tumoral cells. Recently it has been reported that in pituitary 
adenomas both the PI3K/AKT and MAPK pathway are overexpressed, which results in 
inhibition of cell cycle inhibitors [149-150]. I have shown the increased mRNA 
expression of NOD receptors in a subset of human pituitary adenomas; they might 
sustain survival through PI3K/AKT pathway.  
There are many factors known that have an influence on CDK4/Cyclin D and 
CDK2/Cyclin E complexes, which in turn are known to regulate the G1/S transition. The 
requisite initial steps for cell cycle progression together with the influence of substrates 
such as pRb (Retinoblastoma) and pGSK-3β (glycogen synthase kinase- 3β), followed by 
factors involved in cyclin-dependent kinase inhibitors, will be discussed in detail in the 
following paragraph. After receiving a mitogenic signal, the Cyclin D is the first cyclin 
produced in the cell cycle and after binding to CDK4, the complex will lead to the initial 
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phosphorylation of Rb. Western Blot analysis uncovered increased levels of Cyclin 
D1/D3-CDK4 and Cyclin E-CDK2 in AtT20 cells after treatment with NOD ligands. As I 
could show increased phosphorylation of ERK 1/2 and P38, and these are mainly 
associated with proliferation, the initial step of a mitogenic signal is probably initiated 
by phosporylation of these two MAP kinases. ERK 1/2 is known to be involved in direct 
control of Cyclin D1 gene expression and P38 increases nuclear CDK2 activity [55, 151]. 
With respect to cell cycle progression, AKT has been shown to be involved in preventing 
Cyclin D1 degradation [158]. Thus, Cyclin D expression and stability is increased in 
different ways.  
More recently it has been shown that AKT could negatively inﬂuence the expression and 
localization of cell cycle inhibitors such as p21 and p27 directly or indirectly. This event 
takes place by blocking FOXO transcription activity and its target, the p27 tumor 
suppressor gene, or by suppressing p53 activity and its target the p21 tumor suppressor 
gene [112, 152]. These findings match perfectly to the results obtained in this study, as it 
has been shown that AKT phosphorylation took place in response to NOD stimulation 
and its subsequent targets, as there are FOXO and p53, are blocked and are therefore not 
able to fulfill their duties by inducing p21 and p27 expression [62, 117, 153]. However, 
in this specific case it still remains to be clarified whether AKT executes this effect 
directly or indirectly. The connection between AKT and p53 will be discussed in chapter 
5.3.2. 
The best described function of the Rb substrate is to restrict cell cycle progression 
within G1-phase. Rb phosphorylation and its subsequent inactivation requires an initial 
phosphorylation by CDK4/Cyclin D complexes. It has been observed that Cyclin D1 is 
required for phosphorylation at the Ser780 residue [154-155]. GSK-3β inhibits its kinase 
activity upon phosphorylation through AKT pathway and subsequent to this event, the 
degradation of Cyclin D1 will not occur, so that the cell cycle could proceed [55]. As I 
already observed increased protein levels of Cyclin D1, the activation status of Rb and 
GSK-3β was investigated. Due to hyperphosphorylation of Rb, free E2F could promote 
transcription from a number of promoters and several proteins needed for cell cycle 
progression. The inactivation of GSK-3β also supports the cell cycle progression, as the 
degradation of Cyclin D1 will not take place.   
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Figure 50 sums up the preceding paragraphs. 
 
 
 
Fig. 50: Illustration of cell cycle progression in AtT20 cells. Initial mitogenic signal by ERK 1/2 and P38. 
CDK4/Cyclin D complex phosphorylates Rb, free E2F will induce transcription of Cyclin E. AKT 
phosphorylates and therefore inactivates GSK-3β and FOXO. Moreover, p53 is inhibited by AKT. FOXO and 
p53 are not able to induce expression of cyclin-dependent kinase inhibitors p27 and p21. 
5.3.2 Survival 
 
As several components involved in programmed cell death were negatively regulated by 
NOD ligands, this section is related to increasing cellular events linked to survival, and 
decreasing cellular events leading to apoptosis. The first part will describe the 
involvement of PI3K/AKT signaling pathway and its downstream components. The 
second part will focus on JNK signaling.  
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The PI3K (Phosphoinositide 3-kinase) signaling pathway is involved in a large number of 
cellular functions including proliferation, cell growth and survival. Upon activation, the 
PI3K leads to the activation of many downstream components. The following part of the 
discussion will focus on PI3K and its downstream targets as well as on its antagonist, the 
tumor suppressor PTEN (phosphatase and tensin homolog deleted at chromosome 10). 
As a primary mediator of PI3K signaling, the role of AKT in supporting tumorigenesis is 
due to phosphorylation of key regulatory molecules involved in apoptosis, cell growth 
and proliferation. Related to this study, the tumor suppressor p53, FOXO (forkhead 
family of transcription factors) and mTOR (mammalian target of rapamycin) have been 
included [156-157]. The substrates GSK-3β and FOXO are known to be involved in both 
cell cycle progression and survival, but their main effect is to target cell cycle 
progression, as has been discussed in the previous chapter.  
As I observed increased levels of AKT after treatment with NOD ligands and decreased 
levels after knocking down NOD1 and NOD2 using the siRNA technique, the specific 
effect of the receptors could be proven. Thus, the PI3K/AKT signaling pathway seemed 
to be functional in AtT20 cells upon NOD receptor activation. 
PTEN attenuates signaling downstream of activated PI3K and influences many functions, 
including cell growth, survival, proliferation, migration and metabolism [158]. Western 
blot analysis revealed low PTEN levels that fit to the elevated AKT levels after NOD 
ligand treatment. So, the PI3K signaling pathway did not seem to be attenuated by its 
antagonist. Another important tumor suppressor conntected to the PI3K/AKT pathway 
is the p53 transcription factor. An impairment of p53 function leads to dysregulation of 
apoptosis signaling pathways and increases tumorigenesis. NOD receptor activation and 
NOD2 overexpression led to a suppression of p53. BAX as a representative of the pro-
apoptotic part of the BCL-2 family is known as a main target of p53 [136]. In response to 
apoptotic stimuli, BAX undergoes a conformational change to expose domains vital for 
its apoptosis function and induces mitochondrial permeabilization [159]. BAX 
expression was inhibited after treatment with NOD ligands. Interestingly, a connection 
of PTEN and p53 has recently been established, showing that the absence or mutation of 
PTEN leads to subsequent loss of the p53 protein and an inability of cells to respond to 
DNA-damaging agents with an apoptotic response [160].  
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PI3K/AKT signaling is known to promote translocation of MDM2 (Murine Double 
Minute 2) from the cytoplasm into the nucleus, where it negatively regulates p53 [117]. 
AKT is moreover able to induce survival through IKK (I kappaB kinase) and therefore 
inducing the activation of NF-κB [112]. As has been shown here, p53 was suppressed 
and activation of NF-κB could be shown on both transcriptional and protein levels. The 
NF-κB pathway targets genes, that regulate physiological processes ranging from cell 
proliferation to cell death. A strong correlation has been established between 
constitutively expressed NF-κB and chronic inflammation, which in turn is a 
determinant in the development of many cancers [100-101]. BCL-2 is one of the survival 
representatives of the BCL-2 family and is regulated by NF-κB [139]. Experiments in 
which NOD2 was overexpressed, suggest that BCL-2 is upregulated. Apart from BCL-2, 
NF-κB could also induce the expression of XIAP (X-linked Inhibitor of Apoptosis) and as 
shown in chapter 4.5.2, XIAP protein expression was enhanced after NOD receptor 
activation. XIAP is known to stop apoptotic cell death by binding and inhibiting caspases 
3, 7 and 9, respectively [137]. Paradoxically, a growing body of evidence also exists to 
support a modulatory role for XIAP in NF-κB activation. Earlier studies revealed the 
ability of ectopically expressed XIAP to activate NF-κB-responsive reporter activity 
[161]. That could mean that in the case of survival, expression of XIAP would lead to 
augmented NF-κB activity and to an amplification of the anti-apoptotic response, 
besides inhibition of caspases. There is recent evidence that XIAP also promotes the 
activation of PI3K/AKT pathway and that increased levels of XIAP directly correlate with 
lowered protein levels of PTEN [162-163].   
mTOR (mammalian Target of Rapamycin) is another important downstream target of 
PI3K/AKT signaling that regulates cell growth and metabolism in response to 
environmental triggers. The mTORC1 complex is composed of the mTOR catalytical 
subunit, Raptor, which is the regulatory associated protein of mTOR, PRAS40 and the 
protein mLST8. One of the most extensively characterized downstream targets of 
mTORC1 is the ribosomal protein S6 kinase, p70S6K. This kinase is crucial to the 
regulation of protein synthesis. Thus, activation of mTOR may provide tumor cells with a 
growth advantage by promoting protein synthesis [118]. As shown in chapter 4.6.2, 
mTOR, Raptor, as well as p70S6K have been enhanced after treatment with NOD ligands. 
Even though the results have shown evidence that in AtT20 cells the mTOR signaling 
pathway is active, the mediated increase in cell mass remains to be shown. 
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The JNK signaling pathway is known to be required for embryonic morphogenesis and 
contributes to the regulation of multiple physiological processes. Indeed, the JNK 
pathway has been implicated in both apoptosis and survival signaling. The specific role 
of JNK may therefore depend upon the cellular context. In addition it has been reported 
that JNK also plays an important role in tumor cells. The general consequence of chronic 
JNK signaling is apoptosis. JNK is known to target the AP-1 transcription factor [164]. 
The data revealed decreased protein levels of phosphorylated JNK and subsequently 
decreased AP-1 transcriptional activity. It may be considered as an anti-apoptotic event 
in this context. However, the precise role of AP-1 in the response of JNK activation is 
likely to be modified by the activity of other transcription factors that interact with AP-1 
on the promoters of target genes. The decision whether AP-1 is oncogenic or anti-
oncogenic might depend on tumor type, tumor stage and also the genetic background of 
the tumors. Although the results on JNK and AP-1 have been considered as an anti-
apoptotic event, the question concerning the ability of cells to interpret JNK activation 
that could lead to different outcomes in different contexts, still remains unresolved and 
requires more investigation. 
The last chapter could be concluded by saying that NOD receptor activation seems to 
play an important role to the survival of pituitary tumor cells by regulating PI3K/AKT 
signaling, and as a consequence of this, modulating a variety of AKT downstream targets. 
Figure 51 represents a general view of the topics discussed in the previous paragraphs. 
 
 
 
 
 
 
 
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 51: Illustration of NOD induced cell survival in AtT20 cells. Low levels of PTEN cannot suppress PI3K 
and lead to loss of p53. Elevated PI3K activates AKT, which in turn activates NF-κB and mTOR. Activated 
NF-κB will induce pro-survival proteins, XIAP and BCL-2. p53 is inhibited by AKT and therefore the pro-
apoptotic BAX protein expression is also reduced, inhibiting apoptotic events. Low levels of 
phosphorylated JNK could not induce the transcription factor AP-1, thus preventing the cells from cell 
death. 
5.4 Concluding remarks and future perspectives 
In summary it can be said, that the results represent a new perspective into infection-
associated tumorigenesis, and illustrate the importance of immune receptors in the 
pituitary gland and possibly in pituitary adenomas. Overall, pituitary adenomas 
progression may employ the sustained activation of NOD signaling pathways. A 
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dysregulation of NOD signaling can affect the host-environment interaction and thus 
contribute to the pathogenesis of this disease.  
In the following last paragraphs of the thesis, some future perspectives of NOD receptor 
signaling are provided. Cells of all organisms transiently or continuously suffer from a 
variety of damages from internal as well as external physico-chemical and biotic factors 
during their lifespan. Therefore, the cells have developed several strategies to repair the 
damage, and if not possible, to eliminate damaged cells. In these processes, so called 
Heat Shock Proteins (HSPs), produced by stressed cells, play an important role [165]. At 
least for HSP90 it has been shown that it interferes with NOD receptors [166]. Malignant 
cells are permanently exposed to stress. HSP can be actively secreted by tumor cells or 
released by apoptotic tumor cells and can then directly interfere with NOD receptors. 
From preliminary data performed during this study, HSP90 mRNA levels were higher in 
pituitary adenomas in comparison with normal human pituitaries. Based on this, it could 
be hypothesized that HSP proteins act as an endogenous ligand for NOD receptors` 
mediating effects, and that they act in synergy to influence pituitary tumor development. 
Thus, blocking the action of bacterial cell wall components or HSP through NOD would 
then suppress tumor development and may represent a future therapeutic option in the 
treatment of pituitary tumors. Inhibition could be performed by blocking intracellular 
signaling pathways and by downregulating components of NOD signaling on 
transcriptional and translational level.  
As NOD ligands seem to not influence normal rat pituitary ACTH secretion, but show 
effects on ACTH secretion in tumor cells, their contribution to pathogenesis could be 
emphasized. Thus, NOD receptors could be considered as therapeutic targets; the 
modulation of NOD receptors activity might slow down or even stop pituitary tumor 
progression. Here, clearly more work is needed.  
Therapeutic antibodies are a fast growing class of human therapeutics. As they provide 
high specificity, they represent ideal agents for blocking certain processes in tumor 
development. They can be used to capture or eliminate tumor growth-supporting 
factors, and therefore to reduce the level of tumorigenic factors. Other antibodies are 
used to target epitopes on the cell surface involved in receptor-ligand binding. 
Previously it has been shown that My4, an antibody preventing TLR4/CD14 interaction, 
blocked LPS induced IL-6 secretion in TtT/GF pituitary tumor cells [167-168]. Recently, 
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we could show that in TtT/GF pituitary tumor cells, TLR4 and NOD receptors act in a 
synergistical manner to cause effects [80]. As TLR4 is also expressed in AtT20 tumor 
cells, neutralizing antibodies might prevent the cells from proliferation and growing. 
Since no corresponding tools for targeting intracellular NODs exist by now, these effects 
could only be tested on TLR4 mediated effects, or on effects meditated through the 
synergy of TLR4 and NODs.  
RNA interference is an effective gene-silencing tool for research, as through silencing 
NOD1 and NOD2 the stimulatory effects on proliferation, survival and growth of 
pituitary tumor cells could be suppressed. Many difficulties need to be solved until RNA 
interference will be applicable as a treatment for patients, but they represent promising 
future cancer therapeutics and may have potential in future clinical treatment concepts 
[169].   
As a chronic bacterial infection through cell wall components may act tumorigenic also 
in pituitary adenoma, the inﬂammation-cancer link affirms that targeting the aberrant 
inﬂammatory process is an important point in the battle against cancer. Despite 
extensive research, the pathogenesis of the majority of pituitary adenomas remains to 
be clariﬁed, as well as the investigation of the most effective way to pharmacologically 
inhibit proliferation, survival and growth of pituitary tumor cells, especially when 
related to inflammation induced tumorigenesis.  
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6. Summary 
 
Although extensive evidence connects the immune system with tumor development and 
progression, the role of NOD (nucleotide oligomerization domain) receptor signaling in 
tumor progression and pathophysiology of tumors in general is still poorly understood. 
This study asks whether NOD receptor activation may play a role in the pathophysiology 
of the pituitary gland by modulating survival signaling pathways and the activity of 
genes related to proliferation, survival and death. NOD1 and NOD2 were shown to be 
expressed in the pituitary gland and in AtT20 cells, and the expression was increased in 
a considerable proportion of human pituitary adenomas in comparison with normal 
pituitaries. NOD1 ligand (iE-DAP) and NOD2 ligand (MDP) induced cell proliferation in 
pituitary adenomas and ACTH secreting cell line AtT20; consistent with this, NOD 
ligands induced increased levels of G1 CDKs and cyclins. NOD receptor activation also 
downregulated or inactivated cell cycle regulators (Rb, FOXO and GSK-3β) and cyclin-
dependent inhibitors (p21 and p27). This study also showed that NOD ligands activated 
NF-κB and MAPK signaling, which are known to affect important events to cancer cells. 
They also activated the PI3K/AKT signaling in AtT20 cells by inducing the 
phosphorylation of AKT, mTOR, the AKT mammalian target of rapamycin, and p70S6K. 
In contrast, the downregulation of tumor suppressors was reflected by decreased levels 
of PTEN (phosphatase and tensin homolog), p27 and p53. Pro-apoptotic molecules, 
namely BAX, p-JNK and AP-1, were all downregulated, whereas anti-apoptotic 
molecules, like BCL-2 and XIAP, were upregulated. This study strongly supports the 
hypothesis that NOD activation promotes the survival of pituitary tumoral cells through 
different pathways and proteins affecting the fate of a cell. The signaling axis of NOD 
receptors may promote pituitary cancer progression, but would also be an attractive 
target for therapy.  
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7. Zusammenfassung 
 
Obwohl bereits eindeutig bewiesen, dass das Immunsystem mit der Entstehung von 
Tumorerkrankungen in direkten Zusammenhang gebracht werden kann, ist die Rolle 
von NOD (nucleotide oligomerization domain) Proteinen bezüglich der 
Tumorprogression und Pathophysiologie von Tumoren bislang nur mangelhaft 
beschrieben. Demzufolge wurde in dieser Dissertation überprüft, ob die Aktivierung der 
intrazellulären NOD-Rezeptoren, und die daraus resultierende Regulation 
unterschiedlicher Signalwege und Aktivierung von Genen, welche im Zusammenhang 
mit Proliferation, Überleben und Zelltod stehen, einen kritischen Punkt in der 
Pathophysiologie von Hypophysentumoren darstellen könnte. Die Expression von NOD1 
und NOD2 konnte in der Hypophyse und in AtT20-Zellen nachgewiesen werden. Diese 
Studie offenbarte eine gesteigerte mRNA-Expression von NOD1 und NOD2 in einem 
beträchtlichen Anteil an humanen Hypophysenadenome im Vergleich zu normalen 
humanen Hypophysen. iE-DAP als NOD1-Ligand und MDP als NOD2 Ligand, regten beide 
die Proliferation in der ACTH produzierenden Zelllinie AtT20 und in humanen 
Hypophysenadenome an. Die gezeigte Proliferation konnte durch eine sichtlich erhöhte 
Proteinexpression von G1 Cyclin-abhängigen Kinasen (CDK) und deren Cycline, welches 
Indikatoren für einen voranschreitenden Zellzyklus darstellen, bekräftigt werden. Im 
Zuge der NOD-Rezeptoren-Aktivierung wurden einige Regulatoren des Zellzyklus (Rb, 
FOXO und GSK-3β) und einige Cyclin-abhängige Inhibitoren (p21 und p27) inaktiviert 
oder herunterreguliert. Diese Studie belegt weiterhin, dass die NOD-Liganden 
unterschiedliche Signalwege aktivieren, darunter NF-κB and MAP-Kinasen, die dafür 
bekannt sind, bedeutende Ereignisse in einer Zelle zu beeinflussen. Durch 
Phosphorylierung von AKT, mTOR und p70S6K aktivierten die NOD-Liganden zusätzlich 
den PI3K/AKT Signalweg. Im Gegensatz dazu, wurden Tumorsuppressorgene wie PTEN 
(phosphatase and tensin homolog), p27 und p53 herunterreguliert. Pro-apoptotische 
Moleküle, wie BAX, p-JNK und AP-1 wurden alle inhibiert, wohingegen anti-apoptotische 
Moleküle, wie BCL-2 und XIAP, hochreguliert wurden. Durch den Einfluss der NOD-
Rezeptoren auf unterschiedliche Signalwege und Proteine, die bedeutend für das 
Schicksal einer Zelle sind, bekräftigt diese Studie die Hypothese, dass eine NOD-
Rezeptor-Aktivierung das Überleben von Hypophysentumorzellen unterstützt. Die NOD- 
Signalwege können zwar die Weiterentwicklung von Hypophysentumoren unterstützen, 
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aber gleichzeitig auch einen attraktiven Ansatzpunkt zur Therapie von 
Hypophysentumoren darstellen.  
  
100 
 
8. References 
 
[1] Horvath E, Kovacs K (1988) Pituitary gland. Pathol Res Pract 183, 129-142 
[2] Furth, J., E. L. Gadsen, and A. C. Upton (1953) ACTH secreting transplantable pituitary 
tumors. Proc. Soc. Exp. Biol. Med. 84, 253-254 
[3] Buonassisi V, Sato G, Cohen AI (1962) Hormon - producing cultures of adrenal and 
pituitary tumor origin. Biochemistry 48, 1184-1190 
[4] Benjannet, S., Rondeau, N., Day, R., Chretien, M., Seidah, N.G. (1991) PC1 and PC2 are 
proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of 
basic residues. Proc. Natl. Acad. Sci. USA 88, 3564–3568 
[5] Bloomquist, B.T., Eipper, B.A., Mains, R.E. (1991) Prohormoneconverting enzymes: 
regulation and evaluation of function using antisense RNA. Mol. Endocrinol. 5, 2014–
2024  
[6] Fickel, J., Savoly, S., Vogel, U., Furkert, J., Melzig, M. (1994) The proopiomelanocortin 
(POMC) gene expression of AtT20 mouse pituitary cells is dependent on cell culture 
conditions. Cell Mol. Biol. (Noisyle-grand) 40, 201–209 
[7] Li, Q.L., Jansen, E., Friedman, T.C. (1999) Regulation of prohormone convertase 1 
(PC1) by gp130-related cytokines. Mol. Cell. Endocrinol. 158, 143–152 
[8] Low, M.J., Liu, B., Hammer, G.D., Rubinstein, M., Allen, R.G. (1993) Post-translational 
processing of proopiomelanocortin (POMC) in mouse pituitary melanotroph tumors 
induced by a POMC-simian virus 40 large T antigen transgene. J. Biol. Chem. 268, 24967–
24975 
[9] Schnabel, E., Mains, R.E., Farquhar, M.G. (1989) Proteolytic processing of pro 
ACTH/endorphin begins in the golgi complex of pituitary corticotropes and AtT-20 cells. 
Mol. Endocrinol. 3, 1223–1235 
[10] Tanaka, S., Nomizu, M., Kurosumi, K. (1991) Intracellular sites of proteolytic 
processing of pro-opiomelanocortin in melanotrophs and corticotrophs in rat pituitary. 
J. Histochem. Cytochem. 39, 809–821 
101 
 
[11] Zhou, A., Mains, R.E. (1994) Endoproteolytic processing of proopiomelanocortin 
and prohormone convertases 1 and 2 in neuroendocrine cells overexpressing 
prohormone convertases 1 or 2. J. Biol. Chem. 269, 17440–17447 
[12] Fagarasan, M.O., Eskay, R., Axelrod, J. (1989) Interleukin 1 potentiates the secretion 
of β-endorphin induced by secretagogues in a mouse pituitary cell line (AtT-20). Proc. 
Natl. Acad. Sci. USA 86, 2070–2073 
[13] Fukata, J., Usui, T., Naitoh, Y., Nakai, Y., Imura, H. (1989) Effects of recombinant 
human interleukin-1α,-1β 2 and 6 on ACTH synthesis andrelease in the mouse pituitary 
tumour cell line AtT-20. J. Endocrinol. 122, 33–39 
[14] Autelitano, D.J. (1994) Glucocorticoid regulation of c-fos, c-jun and transcription 
factor AP-1 in the AtT-20 corticotrope cell. J. Neuroendocrinol. 6, 627–637 
[15] Chen, F., Watson, C.S., Gametchu, B. (1999) Multiple glucocorticoid receptor 
transcripts in membrane glucocorticoid receptor-enriched S-49 mouse lymphoma cells. 
J. Cell Biochem. 74, 418–429 
[16] Clark, T.P., Kemppainen, R.J. (1994) Glucocorticoid negative feedback in sheep 
corticotrophs: a comparison with AtT-20 corticotroph tumor cells. Am. J. Physiol. 267, 
463–469 
[17] Harrison, R.W., Miyabe, S. (1981) Steroid structure and nuclear translocation of 
glucocorticoid receptors in intact AtT-20 mouse pituitary tumor cells. J. Steroid Biochem. 
15, 393–396 
[18] Svec, F., Rudis, M. (1981) Glucocorticoids regulate the glucocorticoid receptor in the 
AtT-20 cell. J. Biol. Chem. 256, 5984–5987 
[19] Thermos, K., Reisine, T. (1988) Somatostatin receptor subtypes in the clonal 
anterior pituitary cell lines AtT-20 and GH3. Mol. Pharmacol. 33, 370–377 
[20] Bristulf, J., Simoncsits, A., Bartfai, T. (1991) Characterization of a neuronal 
interleukin-1 receptor and the corresponding mRNA in the mouse anterior pituitary cell 
line AtT-20. Neurosci. Lett. 128, 173–176 
102 
 
[21] Kobayashi, H., Fukata, J., Tominaga, T., Murakami, N., Fukushima, M., Ebisui, O., 
Segawa, H., Nakai, Y., Imura, H. (1992) Regulation of interleukin-1 receptors on AtT-20 
mouse pituitary tumour cells. FEBS Lett. 298, 100–104 
[22] Webster, E.L., Tracey, D.E., De Souza, E.B. (1991) Upregulation of interleukin-1 
receptors in mouse AtT-20 pituitary tumor cells following treatment with corticotropin-
releasing factor. Endocrinology 129, 2796–2798 
[23] Clark, M.A., Korte, A., Myers, J., Egan, R.W. (1992) High afﬁnity histamine H3 
receptors regulate ACTH release by AtT-20 cells. Eur. J. Pharmacol. 210, 31–35 
[24] Clark, M.A., Korte, A., Egan, R.W. (1993) Guanine nucleotides and pertussis toxin 
reduce the afﬁnity of histamine H3 receptors on AtT-20 cells. Agents Actions 40, 129-
134 
[25] Kamijo, K., Sato, M., Saito, T., Yachi, A., Minase, T. (1991) Effects of bromocriptine on 
experimental GH3 cell tumors. Patho.l Res. Pract. 187, 593–597 
[26] Kuzhikandathil, E.V., Yu, W., Oxford, G.S. (1998) Human dopamine D3 and D2L 
receptors couple to inward rectiﬁer potassium channels in mammalian cell lines. Mol. 
Cell Neurosci. 12, 390–402 
[27] Williams, J.C., Stone, D., Smith-Arica, J.R., Morris, I.D., Lowenstein, P.R., Castro, M.G., 
(2001) Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses 
growth of estrogen-induced pituitary prolactinomas. Mol. Ther. 4, 593–602 
[28] Akiyama, K., Vickroy, T.W., Watson, M., Roeske, W.R., Reisine, T.D., Smith, T.L., 
Yamamura, H.I. (1986) Muscarinic cholinergic ligand binding to intact mouse pituitary 
tumor cells (AtT-20/D16-16) coupling with two biochemical effectors: adenylate cyclase 
and phosphatidylinositol turnover. J. Pharmacol. Exp. Ther. 236, 653–661 
[29] Heisler, S. (1985) Inhibition of ACTH secretion in mouse pituitary tumor cells by 
activation of muscarinic cholinergic receptors. Can. J. Physiol. Pharmacol. 63, 723–730 
[30] Lenz, W., Petrusch, C., Jakobs, K.H., van Koppen, C.J. (1994) Agonist-induced down 
regulation of the m4 muscarinic acetylcholine receptor occurs without changes in 
receptor mRNA steady-state levels. Naunyn Schmiedebergs Arch. Pharmacol. 350, 507–
513 
103 
 
[31] Hanahan, D., and Weinberg, R.A. (2000) The hallmarks of cancer. Cell. 100:57–
70 
[32] Vogelstein, B. & Kinzler, K.W. (1993) The multistep nature of cancer. Trends Genet 
9, 138-41 
[33] Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP (1998) Alterations in DNA 
methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 72:141-96 
[34] Bertherat J, Chanson P, Montminy M (1995) The cyclic adenosine 3',5' 
monophosphate-responsive factor CREB is constitutively activated in human 
somatotroph adenomas. Mol Endocrinol. 9:777-83  
[35] Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) 
Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N 
Engl J Med. 325: 1688-95  
[36] Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, Farrell WE 
(1999) Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic 
human pituitary tumors. Clin Cancer Res. 5: 2133-9 
[37] Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z (1996) Localization of Epidermal 
Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary 
Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study. Endocr Pathol. 
7: 63-70 
[38] Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, 
Petrangeli E, Losa M, Stalla GK, Pagotto U (2004) Expression of epidermal growth factor 
receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J 
Endocrinol. 183: 385-94 
[39] Ezzat S, Smyth HS, Ramyar L, Asa SL (1995) Heterogenous in vivo and in vitro 
expression of basic fibroblast growth factor by human pituitary adenomas. J Clin 
Endocrinol Metab. 80: 878-84 
[40] Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL (2002) Targeted expression of a human 
pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary 
tumorigenesis. J Clin Invest. 109: 69-78 
104 
 
[41] Theodoropoulou M, Cavallari I, Barzon L, D'Agostino DM, Ferro T, Arzberger T, 
Gruebler Y, Schaaf L, Losa M, Fallo F, Ciminale V, Stalla GK, Pagotto U (2004) Differential 
expression of menin in sporadic pituitary adenomas. Endocr Relat Cancer. 11: 333-44 
[42] Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D (1995) Frequent 
loss of heterozygosity at the retinoblastoma susceptibility gene (Rb) locus in aggressive 
pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than Rb. 
Cancer Res. 55: 1613-6 
[43] Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRb 
expression in pituitary adenomas is associated with methylation of the RB1 CpG island. 
Cancer Res. 60: 1211-6 
[44] Woloschak M, Yu A, Post KD (1997) Frequent inactivation of the p16 gene in human 
pituitary tumours by gene methylation. Mol Carcinogen 19:221–224 
[45] Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins 
PJ, Monson JP, Besser GM, Lowe DG, Grossman AB (1999) Low expression of the cell 
cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant 
pituitary tumors. J Clin Endocrinol Metab. 84: 3823-30 
[46] Pagotto U, Arzberger T, Theodoropoulou M, Grubler Y, Pantaloni C, Saeger W, Losa 
M, Journot L, Stalla GK, Spengler D (2000) The expression of the antiproliferative gene 
ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res. 60: 
6794-9 
[47] (Hartwell, L. & Weinert, T. (1989) Checkpoints: controls that ensure the order of 
cell cycle events. Science 246, 629–634 
[48] Malumbres, M. & Barbacid, M. (2001) To cycle or not to cycle: a critical decision in 
cancer. Nature Rev Cancer 1, 222-231  
[49] Morgan DO: The Cell Cycle: Principles of Control. (2007) London: New Science 
Press Ltd; ISBN: 978-0-9539181-2-6 
[50] Hochegger H, Takeda S, Hunt T. (2008) Cyclin-dependent kinases and cell-cycle 
transitions: does one fit all? Nat Rev Mol Cell Biol 9(11):910-916 
105 
 
[51] Pavletich, N. P. (1999) Mechanisms of cyclin-dependent kinase regulation: 
structures of Cdks, their cyclin activators and Cip and Ink inhibitors. J. Mol. Biol. 287, 
821–828 
[52] Serrano, M., Lin, A., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997) Oncogenic ras 
provokes premature cell senescence associated with accumulation of p53 and 
p16INK4a. Cell 88(5): 593-602 
[53] Nakayama, K., and Nakayama, K. (1998) Cip/Kip cyclin-dependent kinase 
inhibitors: Brakes of the cell cycle engine during development. Bioessays20, 1020–1029 
[54] Ekholm, S. V. & Reed, S. I. (2000) Regulation of G1 cyclin-dependent kinases in the 
mammalian cell cycle. Curr.Opin. Cell Biol. 12, 676–684 
[55] Alt, J. R., Cleveland, J. L., Hannink, M. & Diehl, J. A. (2000) Phosphorylation-
dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular 
transformation, Genes Dev. 14, 3102–3114 
[56] Fantl, V., Stamp, G., Andrews, A., Rosewell, I. & Dickson, C. (1995) Mice lacking cyclin 
D1 are small and show defects in eye and mammary gland development. Genes Dev. 
9,2364–2372 
[57] Morgan, D. O. (1997) Cyclin-dependent kinases: engines, clocks, and 
microprocessors. Annu. Rev. Cell Dev. Biol. 13,261–291 
[58] Ezhevsky, S. A., Ho, A., Becker-Hapak, M., Davis, P. K. & Dowdy, S. F. (2001) 
Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-
dependent kinase complexes in vivo. Mol. Cell. Biol. 21, 4773–4784 
[59] Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 
2:594–604 
[60] Hollstein M, Rice K et al (1994) Database of p53 gene somatic mutations in human 
tumors and cell lines. Nucleic Acids Res 22:3551–3555 
[61] Wolff S, Erster S, Palacios G., Moll UM (2008) p53’s mitochondrial translocation and 
MOMP action is independent of Puma and Bax and severely disrupts mitochondrial 
membrane integrity. Cell Res 18:733–744 
106 
 
[62] Fuster, J.J., Sanz-Gonzales, S.M., Moll, U. M. & Andres, V. (2007) Classic and novel 
roles of p53: prospects for anticancer therapy. Trens Mol. Med. 13, 192-199 
[63] Cantley LC & Neel BG (1999) New insights into tumor suppression: PTEN 
suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT 
pathway. PNAS 96 4240–4245 
[64] Maehama, T., Taylor, G. S., & Dixon, J. E. (2001) PTEN AND MYOTUBULARIN: Novel 
Phosphoinositide Phosphatases. Annu Rev Biochem, 70, 247-279 
[65] Vazquez, F., & Sellers, W. R. (2000) The PTEN tumor suppressor protein: an 
antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta, 1470(1), M21 
35 
[66] Li, D. M., & Sun, H. (1997) TEP1, encoded by a candidate tumor suppressor locus, is 
a novel protein tyrosine phosphatase regulated by transforming growth factor beta. 
Cancer Res, 57(11), 2124-2129 
[67] Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., 
Rodgers, L.,McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., 
Hibshoosh, H., Wigler, M. H., & Parsons, R. (1997) PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 
275(5308), 1943-1947 
[68] Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, 
L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., & 
Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at 
chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 15(4), 
356-362 
[69] Maehama, T., & Dixon, J. E. (1998) The tumor suppressor, PTEN/MMAC1, 
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. 
J Biol Chem, 273(22), 13375-13378 
[70] Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., 
Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) Negative regulation of 
PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95(1), 29-39 
107 
 
[71] Sun, H., Lesche, R., Li, D. M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., 
Liu, X., & Wu, H. (1999) PTEN modulates cell cycle progression and cell survival by 
regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling 
pathway. Proc Natl Acad Sci U S A, 96(11), 6199-6204 
[72] Gericke, A., Munson, M. and Ross, A. H. (2006) Regulation of the PTEN phosphatase. 
Gene 374, 1-9 
[73] Lopez-Bergami, P., Fitchman, B., and Ronai, Z. (2008) Understanding signaling 
cascades in melanoma. Photochem. Photobiol. 84, 289–306 
[74] [Akira, S., Uematsu, S. & Takeuchi, O. (2006) Pathogen recognition and innate 
immunity. Cell 124, 783–801 
[75] Han, J., and Ulevitch, R.J. (2005) Limiting inflammatory responses during activation 
of innate immunity. Nat. Immunol. 6:1182-1189 
[76] Jean da Silva Correia, Yvonne Miranda, Nikki Austin-Brown, Jenny Hsu, John 
Mathison, Rong Xiang, Huamin Zhou†, Qinxi Li, Jiahuai Han, and Richard J. Ulevitch 
(2005) Nod1-dependent control of tumor growth. PNAS 1840-1845 
[77] Grace Y. Chen, Michael H. Shaw, Gloria Redondo and Gabriel Núñez (2008) The 
Innate Immune Receptor NOD1 Protects the Intestine from Inflammation-Induced 
Tumorigenesis. Cancer Res. 2008 Dec 15;68(24):10060-7 
[78] Cruickshank SM, Wakenshaw L, Cardone J, Howdle PD, Murray PJ, Carding SR 
(2008) Evidence for the involvement of NOD2 in regulating colonic epithelial cell growth 
and survival. World J. Gastroenterol. 14 5834-41 
[79] Tichomirowa M, Theodoropoulou M, Lohrer P, Schaaf L, Losa M, Uhl E, Lange M, 
Arzt E, Stalla GK & Renner U (2005) Bacterial endotoxin (lipopolysaccharide) stimulates 
interleukin-6 production and inhibits growth of pituitary tumour cells expressing the 
toll-like receptor 4. J. Neuroendocrinol. 17 152-160 
[80] Correa-de-Santana E, Froehlich B, Labeur M, Paez-Pereda M, Theodoropoulou M, 
Monteserin J, Renner U, Stalla G (2009) NOD2 receptors in adenopituitary 
folliculostellate cells: expression and function. J. Endocrinology 
108 
 
[81] Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, et al. (2000) An induced proximity 
model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 
275:27823–31 
[82] Grace Chen, Michael H. Shaw, Yun-Gi Kim, and Gabriel Nuñez (2009) NOD-like 
receptors: Role in Innate Immunity and Inflammatory Disease, Annu. Rev. Pathol. Mech. 
Dis.2009. 4:365–98 
[83] Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. 
Inamura, S. Kusumoto, M. Hashimoto, et al. (2003) Host recognition of bacterial 
muramyl dipeptide mediated through NOD2: implications for Crohn’s disease. J. Biol. 
Chem. 278: 5509–5512 
[84] Kobayashi, K. S., M. Chamaillard, Y. Ogura, O. Henegariu, N. Inohara, G. Nunez, and R. 
A. Flavell (2005) Nod2-dependent regulation of innate and adaptive immunity in the 
intestinal tract. Science 307: 731–734 
[85] Girardin, S. E., I. G. Boneca, L. A. Carneiro, A. Antignac, M. Jehanno, J. Viala, K. Tedin, 
M. K. Taha, A. Labigne, U. Zahringer, et al. (2003) Nod1 detects a unique muropeptide 
from gram-negative bacterial peptidoglycan. Science 300:1584–1587 
[86] Girardin, S. E., I. G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D. J. 
Philpott, and P. J. Sansonetti (2003) Nod2 is a general sensor of peptidoglycan through 
muramyl dipeptide (MDP) detection. J. Biol. Chem. 278:8869–8872 
[87] Chamaillard, Hashimoto, Horie, Masumoto, Su Qiu, Saab, Ogura, Kawasaki, Fukase, 
Kusumoto, Valvano, Foster, Mak, Nuñez & Inohara (2008) An essential role for NOD1 in 
host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nature 
Immunol. 4, 702-707 
[88] Bertin, J., Nir, W.-J., Fischer, C. M., Tayber, O. V., Errada, P. R., Grant, J. R., Keilty, J. J., 
Gosselin, M. L., Robison, K. E., Wong, G. H., Glucksmann, M. A., and DiStefano, P. S. (1999) 
Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates 
NF-kappaB. J. Biol. Chem. 274:12955-12958 
[89] Girardin SE, Tournebize R, Mavris M, Page AL, Li X, et al. (2001) CARD4/Nod1 
mediates NF-κB and JNK activation by invasive Shigella ﬂexneri. EMBO Rep. 2:736–42 
109 
 
[90] Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, et al. (2000) An induced proximity 
model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J. Biol. Chem. 
275:27823–31 
[91] Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, et al. (2002) 
RICK/Rip2/CARDIAK mediates signaling for receptors of the innate and adaptive 
immune systems. Nature 416:194–99 
[92] Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, et al. (2008) A 
polyubiquitination in Nod-induced NF-κB activation. EMBO J. 27:373–83 
[93] Hayden MS & Ghosh S. (2004) Signaling to NF-κB. Genes Dev. 18:2195–224 
[94] Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. (2009) NOD2-
associated diseases: Bridging innate immunity and autoinflammation, Clinical 
Immunology 
[95] Jérôme Viala, Catherine Chaput, Ivo G Boneca, Ana Cardona, Stephen E Girardin, 
Anthony P Moran, Rafika Athman, Sylvie Mémet, Michel R Huerre, Anthony J Coyle, Peter 
S DiStefano, Philippe J Sansonetti, Agnès Labigne, John Bertin, Dana J Philpott & Richard 
L Ferrero (2004) Nod1 responds to peptidoglycan delivered by the Helicobacter pylori 
cag pathogenicity island. Nature Immunol. 5, 1166-1174 
[96] Uemura, Okamoto and Yamamoto (2004) Helicobacter pylori infection and the 
development of gastric cancer. Nature Genet. 36. 476-789 
[97] Hysi P, Kabesch M, Moffatt MF, Schedel M, Carr D, Zhang Y, Boardman B, von Mutius 
E, Weiland SK, Leupold W, Fritzsch C, Klopp N, Musk AW, James A, Nunez G, Inohara N, 
Cookson WO. (2005) NOD1 variation, immunoglobulin E and asthma. Hum. Mol. Genet. 
14. 935-941 
[98] Hayden, M. S. and Ghosh, S. (2004) Signaling to NF-κB. Genes Dev. 18, 2195–2224 
[99] Papa, S., Bubici, C., Zazzeroni, F., Pham, C. G., Kuntzen, C., Knabb, J. R., Dean, K., and 
Franzoso, G. (2006) The NF-κB-mediated control of the JNK cascade in the antagonism of 
programmed cell death in health and disease. Cell Death Differ. 14, 240–253 
110 
 
[100] Karin, M. (2006) Nuclear factor-κB in cancer development and progression. 
Nature 441, 431–436 
[101] Karin, M. and Greten, F. R. (2005) NF-κB: linking inflammation and immunity to 
cancer development and progression. Nat. Immunol. 5, 749–759 
[102] Bradshaw & Dennis (2003) Handbook of cell signaling. Academic Press. ISBN: 
0121245470 / 0-12-124547-0 
[103] Brown MD, Sacks DB. (2008) Compartmentalized MAPK pathways. Handb Exp 
Pharmacol; 186:205–35 
[104] Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH 
(2001) "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological 
functions". Endocr. Rev. 22 (2): 153–83 
[105] Tibbles, L. A. and Woodgett, J. R. (1999) The stress-activated protein kinase 
pathways. Cell Mol. Life Sci. 55, 1230–1254 
[106] Crews, C. M., Alessandrini, A., and Erikson, R. L. (1992) The primary structure of 
MEK, a protein kinase that phosphorylates the ERK gene product. Science 258, 478–480 
[107] Traverse, S., Seedorf, K., Paterson, H., Marshall, C.J., Cohen, P., and Ullrich, A. (1994) 
EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. 
Curr. Biol. 4, 694–701 
[108] Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A.,Ahmad, M. F., Avruch, 
J., and Woodgett, J. R. (1994) The stress-activated protein kinase subfamily of c-Jun 
kinases. Nature 369, 156–160 
[109] Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., and Woodgett, J. R. (1991) 
Phosphorylation of c-Jun mediated by MAP kinases. Nature 353, 670–674 
[110] Iñesta-Vaquera F, Sabio G, Kuma Y, and Cuenda A. (2008) Alternative p38 
Pathways MAPK. Springer Berlin / Heidelberg 17-32 
[111] Tina M. Thornton and Mercedes Rincon (2009) Non-Classical P38 Map Kinase 
Functions: Cell Cycle Checkpoints and Survival. International Journal of Biological 
Sciences 5(1): 44–52. 
111 
 
[112] Engelman, J.A, Luo, J. & Cantley, L. C. (2006) The evolution of phospatidylinositol 
3-kinases as regulators of growth and metabolism. Nature Rev. Genet. 7(8):606-19 
[113] Fruman, D. A., Meyers, R. E. & Cantley, L. C., (1998) Phosphoinositide kinases. 
Annu. Rev. Biochem 67:481-507 
[114] Okano, J., Gaslightwala, I., Birnbaum, M. J., Rustgi, A. K., & Nakagawa, H. (2000) 
Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor 
stimulation. J Biol Chem, 275(40), 30934-30942 
[115] Datta, Dudek, Tao, Masters, Fu, Gotoh and Greenberg (1997) AKT phosphorylation 
of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 
[116] Romashkova, J. A. & Makarov, S. S. (1999) NF-κB is a target of AKT in anti-
apoptotic PDGF signaling. Nature 401, 86–90 
[117] Mayo, L. D. & Donner, D. B. (2001) A phosphatidylinositol 3-kinase/AKT pathway 
promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. 
USA 98, 11598–11603 
[118] Wullschleger, s., Loewith, R. & Hall, M. N. (2007) TOR signaling in growth and 
metabolism. Cell 124(3):471-84 
[119] Zhao, L., Lee, J.Y., Hwang, D.H. (2008) The Phosphatidylinositol 3-Kinase/Akt 
Pathway Negatively Regulates Nod2-Mediated NF-κB Pathway. Biochemical 
Pharmacology. Vol.75, No.7, pp.1515-1525. 
[120] Osaki, M., Oshimura, M., and Ito, H. (2004) PI3K-Akt pathway: its functions and 
alterations in human cancer. Apoptosis 9(6):667-76 
[121] Hardy J. (1979) Recent advances in the treatment and diagnosis of pituitary 
tumours. New York: Raven. pp. 375 ± 388 
[122] Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Müller A, Lange M, Weindl 
A, Stalla GK. (1998) Heterogeneous dopamine D2 receptor subtype messenger 
ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. J Clin 
Endocrinol Metab. 83(4):1368-75 
112 
 
[123] Fire, Montgomery, Kostas, Driver, Mello (1998) Potent and specific genetic 
interference by double stranded RNA in Caenorhabditis elegans. Nature volume 391, 
number 6669, page 806-811 
[124] Stalla G.K., Stalla J., Von Werder K., Müller A., Gerzer R., Höllt V., Jakobs K.H. (1989) 
Nitroimidazole derivates inhibit anterior pituitary cell function apparently by a direct 
effect on the catalytic subunit of the adenylate cyclase holoenzyme. Endocrinology 125, 
699-706 
[125] Murphy EP & Conneely OM (1997) Neuroendocrine regulation of the 
hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. 
Mol. Endocrinol. 11 39-47 
[126] Ting JP, Davis BK (2004) CATERPILLER: a novel gene family important in 
immunity, cell death, and diseases. Annu. Rev. Immunol. 23, 387–414 
[127] Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence J.C. and Abraham R.T. 
(1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin 
by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15, 
5256–5267 
[128] Orban Z, Mitsiades N, Burke TR Jr, Tsokos M, Chrousos GP (2000) Caffeic acid 
phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and 
suppresses acute inflammation. Neuroimmunomodulation 7, 99-105 
[129] Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, 
and Cdk inhibitors in human cancer. Adv. Cancer Res. 68, 67-108 
[130] Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD, Brizuela L, 
Brenner SL, Stouten PF (2005) Understanding and modulating cyclin-dependent kinase 
inhibitor specificity: molecular modeling and biochemical evaluation of 
pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J. Comput. 
Aided. Mol. Des. 19, 111-22 
[131] Farrell WE & Clayton RN (2000) Molecular pathogenesis of pituitary tumors. 
Front. Neuroendocrinology. 21, 174-98 
113 
 
[132] Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, 
Farrell WE, Claret FX, Grossman AB (2002) Expression of phosphorylated p27(Kip1) 
protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. 
Endocrinol. Metab. 87, 2635-43 
[133] Musat M, Korbonits M, Pyle M, Gueorguiev M, Kola B, Morris DG, Powell M, 
Dumitrache C, Poiana C, Grossman AB (2002) The expression of the F-box protein Skp2 
is negatively associated with p27 expression in human pituitary tumors. Pituitary. 5, 
235-42 
[134] Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1992) p53 mutations 
in human cancers. Science 253, 49-53; 1991; Vogelstein, B., and Kinzler, K. W. p53 
function and dysfunction. Cell 70, 523-526 
[135] Vousden KH &Prives C. (2009) Blinded by the Light: The Growing Complexity of 
p53. Cell. 137(3), 413-31. 
[136] Miyashita, T. & Reed, j. C. (1995) Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene. Cell 80, 293-299 
[137] Duckett CS, Li F, Wang Y, Tomaselli KJ, Thompson CB, Armstrong RC (1998). 
"Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and 
cytochrome c". Mol. Cell. Biol. 18 (1), 608–15 
[138] Angel, P. & Karin, M. (1991) The role of Jun, Fos and the AP-1 complex in cell-
proliferation and transformation. Biochim. Biophys. Acta 1072, 129-157 
[139] Arlette B. Werner, Evert de Vries, Stephen W. G. Tait, Ilja Bontjer, and Jannie Borst 
(2002) Bcl-2 Family Member Bfl-1/A1 Sequesters Truncated Bid to Inhibit Its 
Collaboration with Pro-apoptotic Bak or Bax; The Journal of Biological Chemistry, 277, 
22781-22788. 
[140] Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, 
Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. (2003) 
Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications 
for Crohn's disease. J Biol Chem. 2003 Feb 21, 278(8), 5509-12 
114 
 
[141] Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, Fuji A, 
Yuasa T, Manki A, Sakurai Y, Nakajima M, Kobayashi H, Fujiwara I, Tsutsumi H, Utani A, 
Nishigori C, Heike T, Nakahata T, Miyachi Y. (2005) Early-onset sarcoidosis and CARD15 
mutations with constitutive nuclear factor-kappaB activation: common genetic etiology 
with Blau syndrome. Blood. 2005 Feb 1, 105(3), 1195-7 
[142] Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, 
Taniyama K, Sasaki N, Schlemper RJ. (2001) Helicobacter pylori infection and the 
development of gastric cancer. N Engl J Med. 345(11), 784-9 
[143] S. Perwez Hussain, C.C. Harris, (2007) Inﬂammation and cancer: an ancient link 
with novel potentials. Int. J. Cancer 121 2373–2380 
[144] Boutillier AL, Sassone-Corsi P, and Loeffler JP (1991) The protooncogene C-fos is 
induced by corticotropin-releasing factor and stimulates proopiomelanocortin gene 
transcription in pituitary cells. Mol Endocrinol 5, 1301–1310 
[145] Karalis KP, Venihaki M, Zhao J, van Vlerken LE, Chandras C. (2004) NF-kappaB 
participates in the corticotropin-releasing, hormone-induced regulation of the pituitary 
proopiomelanocortin gene. J Biol Chem. 279(12), 10837-40. Epub 2004 Jan 6 
[146] Philips A., Maira M., Mullick A., Chamberland M., Lesage S., Hugo P., and Drouin J. 
(1997) Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol. 
Cell. Biol. (Vol 17) 5946-5951 
[147] Autelitano D.J. (1998) Stress-Induced Stimulation of Pituitary POMC Gene 
Expression Is Associated with Activation of Transcription Factor AP-1 in Hypothalamus 
and Pituitary - Mutual inhibition of DNA binding due to direct protein-protein 
interaction. Brain Research Bulletin. pp. 75-82(8) 
[148] Aksoy E, Vanden Berghe W, Detienne S, Amraoui Z, Fitzgerald KA, Haegeman G, 
Goldman M & Willems F (2005) Inhibition of phosphoinositide 3-kinase enhances TRIF-
dependent NF-κB activation and IFN-beta synthesis downstream of Toll-like receptor 3 
and 4. European Journal of Immunology 35 2200–2209. 
[149] M Muşat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S 
Jordan, D G Morris, M Gueorguiev, M Coculescu, S Basuand and A B Grossman (2005) 
115 
 
Enhanced protein kinase B/Akt signaling in pituitary tumours. Endocrine-Related 
Cancer 12 (2) 423 -433   
[150] E Wlodek, D Dworakowska, C Leontiou, S Igreja, M Góth, M Korbonits & A 
Grossman (2009) Extracellular signal-regulated kinase pathway is over-activated in 
pituitary adenomas. Society for Endocrinology 19, P186 
[151] C Corre `ze, J-P Blondeau and M Pome ´rance (2005) p38 mitogen-activated 
protein kinase contributes to cell cycle regulation by cAMP in FRTL-5 thyroid cells. 
European Journal of Endocrinology (2005) 153, 123–133 
[152] Vivanco, I., and C.L. Sawyers (2002) The phosphatidylinositol 3-kinase AKT 
pathway in human cancer. Nat. Rev. Cancer. 2, 489–501 
[153] Medema, R. H., Kops, G. J., Bos, J. L., and Burgering, B. M., (2000) AFX-like Forkhead 
transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. 
Nature 404, 782–787 
[154] Geng Y, Yu Q, Sicinska E, Das M, Bronson RT, Sicinski P. (2001) Deletion of the 
p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad 
Sci USA 98, 194-9 
[155] M Kitagawa, H Higashi, H K Jung, I Suzuki-Takahashi, M Ikeda, K Tamai, J Kato, K 
Segawa, E Yoshida, S Nishimura, and Y Taya (1996) The consensus motif for 
phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin 
A/E-Cdk2. EMBO J. 15(24),  7060–7069 
[156] Jiang BH and Liu LZ (2008) PI3K/PTEN signaling in tumorigenesis and 
angiogenesis. Biochim Biophys Acta. 1784(1), 150-8 
[157] Liu P, Cheng H, Roberts TM, Zhao JJ. (2009) Targeting the phosphoinositide 3-
kinase pathway in cancer. Nat Rev Drug Discov. 8(8), 627-44 
[158] Endersby R, Baker SJ. (2008) PTEN signaling in brain: Neuropathology and 
tumorigenesis. Oncogene 27, 5416–5430 
[159] Lindsten, T., Ross, A. J., King, A., Zong, W. X., Rathmell, J. C., Shiels,H. A., Ulrich, E., 
Waymire, K. G., Mahar, P., Frauwirth, K., Chen, Y., Wei, M., Eng, V. M., Adelman, D. M., 
116 
 
Simon, M. C., Ma, A., Golden, J. A., Evan, G., Korsmeyer, S. J., MacGregor, G. R., and 
Thompson, C. B. (2000) The combined functions of proapoptotic Bcl-2 family members 
bak and bax are essential for normal development ofmultiple tissues. Mol. Cell 6, 1389–
99. 
[160] Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. (2002) PTEN protects p53 
from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 277(7), 5484-9 
[161] Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. (2000) 
Activation of NF-κB by XIAP, the X chromosome-linked inhibitor of apoptosis, in 
endothelial cells involves TAK1. J Biol Chem. 275, 22064–22068 
[162] Eric Asselin, Yifang, Wang and Benjamin K. Tsang (2001) X-Linked Inhibitor of 
Apoptosis Protein Activates the Phosphatidylinositol 3-Kinase/Akt Pathway in Rat 
Granulosa Cells during Follicular Development. Endocrinology Vol. 142, No. 6 2451-
2457 
[163] Van Themsche C, Leblanc V, Parent S, Asselin E. J (2009) X-linked inhibitor of 
apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and 
compartmentalization. Biol. Chem 31, 284(31), 20462-6 
[164] Ip, Y.T., and Davis, R.J. Signal transduction by the c-Jun N-terminal kinase (JNK)—
from inflammation to development. Curr. Opin. Cell Biol. 10, 205–219, 1998 
[165] Schlesinger MJ (1994) How the cell copes with stress and the function of heat 
shock proteins. Pediatr Res. 36, 1-6. Review 
[166] Mayor A, Martinon F, De Smedt T, Pétrilli V, Tschopp J (2007) A crucial function of 
SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune 
responses. Nat. Immunol. 8, 497-503 
[167] Lohrer P, Gloddek J, Nagashima AC, Korali Z, Hopfner U, Pereda MP, Arzt E, Stalla 
GK, Renner U (2000) Lipopolysaccharide directly stimulates the intrapituitary IL-6 
production by folliculostellate cells via specific receptors and the p38alpha mitogen-
activated protein kinase /nuclear factor-kappaB pathway. Endocrinology 141, 4457-
4465 
117 
 
[168] Gloddek J, Lohrer P, Stalla J, Arzt E, Stalla GK, Renner U (2001) The intrapituitary 
stimulatory effect of lipopolysaccharide on ACTH secretion is mediated by paracrine-
acting IL-6. Exp Clin Endocrinol Diabetes 109, 410-415 
[169] He S, Zhang D, Cheng F, Gong F, Guo Y (2009) Applications of RNA interference in 
cancer therapeutics as a powerful tool for suppressing gene expression. Mol. Biol. Rep. 
Jan 1. Epub ahead of print 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
Acknowledgements 
I am grateful to Prof. Dr. med. Dr. rer. nat. Dr. h.c. F. Holsboer for giving me the opportunity 
to perform my thesis at the Max-Planck-Institute of Psychiatry in Munich. 
 
I would like to acknowledge Prof. Dr. Stalla for providing me such a great opportunity to join 
his research group allowing me to work in such a fascinating field.  
 
I would like to appreciate my supervisor, Dr. Eliane Correa-de-Santana, for sharing her 
knowledge and experience with me. Many thanks also to Dr. Ulrich Renner for correcting the 
thesis and his helpful advices. 
 
My sincere thanks go to Prof. Mac Williams, from the LMU University in Munich, for his great 
support and encouragement.  
 
I also want to mention my colleagues from the lab, Barbara Wölfel, Jose-Luis-Monteserin, 
Vesna Cerovac, Marta Labeur, Marily Theodoropoulou, Bing Shang, Johanna Stalla and 
Monika Makrutzki, for their contribution.  
 
I want to thank my parents and parents-in-law for always believing in me. Their strong 
support and helpful advices during the whole thesis period means a great deal to me. 
Especially Ralf helped me in a way I will never forget. Also many thanks go to Dani and Basti 
for reading the thesis and their general support. Last but not least I want to thank Kira for 
distracting me. I am very happy to have all of you in my life. 
 
Dear Benni, without you all this wouldn’t have been possible. You gave me the feeling that I 
don`t have to shoulder everything alone. I want to thank you for never losing faith in me, 
your encouraging words and for cheering me up. In moments I needed you the most you 
were always there for me, solid as a rock. I hardly could express how much you mean to me, 
but for certain things words are not needed.   
119 
 
Curriculum vitae 
 
 
 
 
 
 
 
Persönliche Daten 
Geburtsdatum und Ort 08. August 1979 in Zeiden (Rumänien) 
Wohnort Knappertsbuschstr. 37, 81927 München 
Familienstand Verheiratet 
Staatsangehörigkeit Deutsch 
 
Ausbildung 
seit März 2008 Promotion am Max-Planck-Institut für Psychiatrie in 
München, Arbeitsgruppe: Neuroendokrinologie 
2002 - 2008 Studium an der Hochschule München 
 Studienrichtung Bioingenieurwesen 
1998 - 2001 Ausbildung zur Reiseverkehrskauffrau beim DER Business 
Travel 
1996 – 1998 Fachoberschule München II, 
 Ausbildungrichtung Wirtschaft, Verwaltung und 
Rechtspflege 
 begleitende fachpraktische Ausbildung 
B I A N C A  F R Ö H L I C H  
120 
 
1992 – 1996 Wilhelm Röntgen Realschule,  
 Ausbildungsrichtung Wirtschaft 
 
Berufliche Stationen 
seit März 2008 DFG (Deutschen Forschungsgesellschaft) geförderte 
Promotion am Max-Planck-Institut für Psychiatrie in 
München, Arbeitsgruppe: Neuroendokrinologie  
Titel des DFG Projektes: Funktion und Wirkmechanismus 
von TLR4 und NOD1/2 in Hypophysentumoren 
 Promotionsthema: NOD proteins and their functional 
relevance to normal and adenomatous pituitary 
Kongresse: 
o Berlin 2009; 2nd European Congress of Immunology 
o Frankfurt 2009; German-Endocrine-Brain-Immune-
Network (GEBIN)  
Posterpräsentation und Vortrag: TLR4 and NOD 
innate immune receptors modulate the response of 
tumor pituitary AtT20 cells through the PI3K/AKT 
survival pathway 
o Bamberg 2008; 12. Jahrestagung der Sektion 
Neuroendokrinologie der Deutschen Gesellschaft 
für Endokrinologie (DGE) 
2007-2008 Diplomarbeit beim Max-Planck-Institut für Psychiatrie in 
München, Arbeitsgruppe: Neuroendokrinologie 
 Thema: Expression, Funktion und 
Wirkungsmechanismus von NOD Proteinen in 
Hypophysentumorzellen 
 
o Anmeldung zum Preisauschreiben des 
bayerischen Staatsministerium für 
Wissenschaft, Forschung und Kunst: „Bayerns 
beste Ingenieurstudentinnen erhalten Preis für 
hervorragende Diplom-, Master- und 
Promotionsarbeiten“  
 
 
 
 
121 
 
Arbeitsspektrum: 
o Molekularbiologische Methoden: 
RNA-Extraktion, Reverse Transkription, PCR, 
Agarosegelelektrophorese 
o Zellkultur:  
Transfektionen, Kultivierung von Zellen 
o Biochemische Methoden: 
Protein Extraktion, SDS-Page, Western Blot, 
Immundetektion von Proteinen, ELISA, 
Immunhistochemie (IHC) 
2006 Praktikum bei Micromet, Inc.                                
Department of Immunotherapy – Research & Development 
 Thema: Generierung eines BiTE-Moleküls 
2004 – 2006 Werkstudentin bei Micromet, Inc.  
o Molekularbiologische Arbeitstechniken: 
Restriktionsenzymverdau, PCR, 
Agarosegelelektrophorese, DNA-Aufreinigung,  
 
Ligation und Transformation von Plasmiden in 
E.coli 
o Zellkultur:  
Transfektionen, Produktion der BiTEs, 
Kultivierung verschiedener Zellarten, Klonierung 
von Zelllinien 
o Durchflußcytometrie (FACS) 
o Proteinaufreinigung:  
Affinitätschromatographie (IMAC), 
Gelfiltrationschromatographie 
o Proteinanalytik: 
SDS-Page, Western Blot 
o Bioassays: 
ELISA, Zytotoxizitätsassays 
2001-2002 Freie Mitarbeiterin im Nachhilfeinstitut Schulfit 
 
2001 Vollzeitbeschäftigung beim DER Business Travel 
 
 
Publikationen: 
Fröhlich B, Labeur M, Paez Pereda M, Buchfelder M, Renner U, Stalla GK, Correa-de-
Santana E (in preparation) NOD1 and NOD2 receptors differently affect proliferation and 
ACTH production in normal and tumoral corticotroph cells. 
122 
 
Correa-de-Santana E, Fröhlich B, Labeur M, Paez-Pereda M, Theodoropoulou M, Monteserin 
J, Renner U, Stalla GK (2009) NOD2 receptors in adenopituitary folliculostellate cells: 
expression and function. J Endocrinol 203:111-122. 
Renner U, Correa de Santana E, Gerez J, Fröhlich B, Haedo M, Paez Pereda M, Onofri C, 
Stalla GK, Arzt E (2009) Intrapituitary expression and regulation of the gp130 cytokine 
interleukin-6 and ist implication in pituitary physiology and pathophysiology. Ann N Y Acad 
Sci 1153:89-97. 
Renner U, Correa-de-Santana E, Fröhlich B, Arzt E, Stalla GK (under revision) The role of 
Toll-like receptor 4 (TLR4) as a putative therapeutic target in disorders of the anterior 
pituitary. Mediators Inflamm.  
 
 
 
 
München, den 23.02.2010 
 
